

Effect of Human Rotavirus Vaccine on Severe Diarrhea

New England Journal of Medicine

362, 289-298

DOI: [10.1056/nejmoa0904797](https://doi.org/10.1056/nejmoa0904797)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Update on Rotavirus Trends and the Importance of Surveillance. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 1130-1132.	1.1	6
3	Vaccines for preventing rotavirus diarrhoea: vaccines in use. , 2010, , CD008521.		35
4	Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. <i>BMJ: British Medical Journal</i> , 2010, 340, c2825-c2825.	2.4	168
5	A Decade of Vaccines: Integrating Immunology and Vaccinology for Rational Vaccine Design. <i>Immunity</i> , 2010, 33, 437-440.	6.6	54
8	Complete genome sequence analysis of candidate human rotavirus vaccine strains RV3 and 116E. <i>Virology</i> , 2010, 405, 201-213.	1.1	38
9	Characterization of genotype G8 strains from Malawi, Kenya, and South Africa. <i>Journal of Medical Virology</i> , 2010, 82, 2073-2081.	2.5	22
10	Nosocomial Rotavirus Gastroenteritis in pediatric patients: a multi-center prospective cohort study. <i>BMC Infectious Diseases</i> , 2010, 10, 235.	1.3	29
11	Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. <i>BMC Biology</i> , 2010, 8, 129.	1.7	232
16	Rotavirus A genotype G1P[8]: a novel method to distinguish wild-type strains from the Rotarix® vaccine strain. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2010, 105, 1068-1072.	0.8	8
17	Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines. <i>Biologics: Targets and Therapy</i> , 2010, 4, 213.	3.0	45
18	Rotavirus in Africa: Shifting the Focus to Disease Prevention. <i>Journal of Infectious Diseases</i> , 2010, 202, S1-S4.	1.9	12
19	Rotavirus Infections and Vaccines. <i>Paediatric Drugs</i> , 2010, 12, 235-256.	1.3	58
20	Pentavalent Rotavirus Vaccine in Developing Countries: Safety and Health Care Resource Utilization. <i>Pediatrics</i> , 2010, 126, e1499-e1506.	1.0	14
21	Inhibitory Effect of Breast Milk on Infectivity of Live Oral Rotavirus Vaccines. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 919-923.	1.1	130
22	Rotarix in Developing Countries: Paving the Way for Inclusion in National Childhood Immunization Programs in Africa. <i>Journal of Infectious Diseases</i> , 2010, 202, S80-S86.	1.9	9
23	Rotavirus Vaccine "A Powerful Tool to Combat Deaths from Diarrhea. <i>New England Journal of Medicine</i> , 2010, 362, 358-360.	13.9	35
24	Rotavirus Vaccine and Severe Diarrhea in African Infants. <i>New England Journal of Medicine</i> , 2010, 362, 1637-1638.	13.9	1
25	Performance of rotavirus vaccines in developed and developing countries. <i>Hum Vaccin</i> , 2010, 6, 532-542.	2.4	174

#	ARTICLE	IF	CITATIONS
26	Global impact of rotavirus vaccines. <i>Expert Review of Vaccines</i> , 2010, 9, 395-407.	2.0	95
27	Development of a <i>Bacillus subtilis</i> -Based Rotavirus Vaccine. <i>Vaccine Journal</i> , 2010, 17, 1647-1655.	3.2	44
28	Recommendations for rotavirus vaccination: A worldwide perspective. <i>Vaccine</i> , 2010, 28, 5100-5108.	1.7	14
29	Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. <i>Vaccine</i> , 2010, 28, 5432-5436.	1.7	66
30	Oral administration of plant-based rotavirus VP6 induces antigen-specific IgAs, IgGs and passive protection in mice. <i>Vaccine</i> , 2010, 28, 6021-6027.	1.7	29
31	Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. <i>Vaccine</i> , 2010, 28, 7507-7513.	1.7	206
32	Dynamic model of rotavirus transmission and the impact of rotavirus vaccination in Kyrgyzstan. <i>Vaccine</i> , 2010, 28, 7923-7932.	1.7	31
33	The uptake of rotavirus vaccine and its effectiveness in preventing acute gastroenteritis in the community. <i>Vaccine</i> , 2010, 29, 91-94.	1.7	33
34	Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2010, 376, 615-623.	6.3	660
35	Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2010, 376, 606-614.	6.3	626
36	Rotavirus: realising the potential of a promising vaccine. <i>Lancet</i> , The, 2010, 376, 568-570.	6.3	54
37	Childhood cancer survivors: stillbirth and neonatal death. <i>Lancet</i> , The, 2010, 376, 570-572.	6.3	6
38	Immune Responses to Rotavirus Infection and Vaccination and Associated Correlates of Protection. <i>Journal of Infectious Diseases</i> , 2011, 203, 188-195.	1.9	158
39	Rotavirus Vaccine RIX4414 (Rotarix®, ¢). <i>Pharmacoeconomics</i> , 2011, 29, 989-1009.	1.7	14
40	Economic evaluations of rotavirus immunization for developing countries: a review of the literature. <i>Expert Review of Vaccines</i> , 2011, 10, 1037-1051.	2.0	27
42	An unusual outbreak of rotavirus genotype G2P[6] during the 2005-2006 epidemic season in Philadelphia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 218-222.	0.8	11
43	Co-dominance of G1 and emerging G3 rotaviruses in Hong Kong: A three-year surveillance in three major hospitals. <i>Journal of Clinical Virology</i> , 2011, 50, 325-333.	1.6	28
45	Maternal antibodies to rotavirus: Could they interfere with live rotavirus vaccines in developing countries?. <i>Vaccine</i> , 2011, 29, 1242-1247.	1.7	58

#	ARTICLE	IF	CITATIONS
46	Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. <i>Vaccine</i> , 2011, 29, 3329-3334.	1.7	28
47	Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix [®] , Φ) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. <i>Vaccine</i> , 2011, 29, 2029-2036.	1.7	33
48	Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. <i>Vaccine</i> , 2011, 29, 6335-6341.	1.7	69
49	Vaccines of the future. <i>Vaccine</i> , 2011, 29, D111-D115.	1.7	13
50	Horizontal transmission of a human rotavirus vaccine strain - A randomized, placebo-controlled study in twins. <i>Vaccine</i> , 2011, 29, 9508-9513.	1.7	67
51	IDEAL vaccines for resource poor settings. <i>Vaccine</i> , 2011, 29, D116-D125.	1.7	53
52	Rotarix [®] : vaccine performance 6 years postlicensure. <i>Expert Review of Vaccines</i> , 2011, 10, 1645-1659.	2.0	40
53	Burden of rotavirus and other enteropathogens among children with diarrhea in Burkina Faso. <i>International Journal of Infectious Diseases</i> , 2011, 15, e646-e652.	1.5	91
54	The African Vaccine-Preventable Diseases Network: a vaccine advocacy initiative. <i>Pan African Medical Journal</i> , 2011, 8, 24.	0.3	4
55	Inhibition of Rotavirus Infectivity by a Neoglycolipid Receptor Mimetic. <i>Nutrients</i> , 2011, 3, 228-244.	1.7	9
56	Decline in Diarrhea Mortality and Admissions after Routine Childhood Rotavirus Immunization in Brazil: A Time-Series Analysis. <i>PLoS Medicine</i> , 2011, 8, e1001024.	3.9	202
57	Rotavirus in South Africa: From discovery to vaccine introduction. <i>The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa</i> , 2011, 26, 184-190.	0.2	6
58	Changes in Childhood Diarrhea Incidence in Nicaragua Following 3 Years of Universal Infant Rotavirus Immunization. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 243-247.	1.1	22
59	Effectiveness of the Monovalent G1P[8] Human Rotavirus Vaccine Against Hospitalization for Severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 396-401.	1.1	103
60	Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 125-130.	1.1	61
61	Case-control Study of the Effectiveness of Vaccination With Pentavalent Rotavirus Vaccine in Nicaragua. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, e209-e215.	1.1	45
62	Viral Gastroenteritis in Adults. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2011, 6, 54-63.	0.5	46
63	Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants. <i>Yearbook of Pediatrics</i> , 2011, 248-250.	0.2	2

#	ARTICLE	IF	CITATIONS
64	Twenty criteria to make the best of scarce health resources in developing countries. <i>BMJ: British Medical Journal</i> , 2011, 343, d7023-d7023.	2.4	10
65	Rotavirus vaccines: safety, efficacy and public health impact. <i>Journal of Internal Medicine</i> , 2011, 270, 206-214.	2.7	31
66	Immunology of gut mucosal vaccines. <i>Immunological Reviews</i> , 2011, 239, 125-148.	2.8	207
67	Transmissible gastroenteritis virus (TGEV)-based vectors with engineered murine tropism express the rotavirus VP7 protein and immunize mice against rotavirus. <i>Virology</i> , 2011, 410, 107-118.	1.1	14
68	Plant-made vaccines in support of the Millennium Development Goals. <i>Plant Cell Reports</i> , 2011, 30, 789-798.	2.8	56
69	Rotarix in Japan: Expectations and Concerns. <i>Biologics in Therapy</i> , 2011, 1, 4.	1.8	0
70	Rotavirus Infection: A Perspective on Epidemiology, Genomic Diversity and Vaccine Strategies. <i>Indian Journal of Virology: an Official Organ of Indian Virological Society</i> , 2011, 22, 11-23.	0.7	11
71	Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants. <i>Science China Life Sciences</i> , 2011, 54, 82-89.	2.3	24
72	Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size. <i>BMC Public Health</i> , 2011, 11, S16.	1.2	51
73	The duration of diarrhea and fever is associated with growth faltering in rural Malawian children aged 6-18 months. <i>Nutrition Journal</i> , 2011, 10, 25.	1.5	45
74	A first report on the characterization of rotavirus strains in Sierra Leone. <i>Journal of Medical Virology</i> , 2011, 83, 540-550.	2.5	15
75	Genotype diversity of group A rotavirus strains in children with acute diarrhea in urban Burkina Faso, 2008-2010. <i>Journal of Medical Virology</i> , 2011, 83, 1485-1490.	2.5	23
76	Cochrane review: Vaccines for preventing rotavirus diarrhoea: vaccines in use. <i>Evidence-Based Child Health: A Cochrane Review Journal</i> , 2011, 6, 567-754.	2.0	1
77	Commentary on "Vaccines for preventing rotavirus diarrhoea: vaccines in use". <i>Evidence-Based Child Health: A Cochrane Review Journal</i> , 2011, 6, 757-758.	2.0	1
78	Molecular characterization of genotype G6 human rotavirus strains detected in Italy from 1986 to 2009. <i>Infection, Genetics and Evolution</i> , 2011, 11, 1449-1455.	1.0	27
79	Optimizing immunization in pediatric special risk groups. <i>Expert Review of Vaccines</i> , 2011, 10, 175-186.	2.0	27
80	Clarity and strength of implications for practice in medical journal articles: an exploratory analysis. <i>BMJ Quality and Safety</i> , 2011, 20, i52-i57.	1.8	7
81	Rotavirus vaccines. <i>Hum Vaccin</i> , 2011, 7, 1282-1290.	2.4	55

#	ARTICLE	IF	CITATIONS
82	Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries. <i>Hum Vaccin</i> , 2011, 7, 734-748.	2.4	62
83	Protective Effect of Natural Rotavirus Infection in an Indian Birth Cohort. <i>New England Journal of Medicine</i> , 2011, 365, 337-346.	13.9	190
84	Vaccines and future global health needs. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011, 366, 2833-2840.	1.8	11
85	Distribution of rotavirus genotypes causing nosocomial and community-acquired acute gastroenteritis at The Children's Hospital of Philadelphia in the new rotavirus vaccine era. <i>Hum Vaccin</i> , 2011, 7, 1118-1123.	2.4	10
86	Rotavirus Prevalence in the Primary Care Setting in Nicaragua after Universal Infant Rotavirus Immunization. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 85, 957-960.	0.6	10
87	Unexpected Benefits of Rotavirus Vaccination in the United States. <i>Journal of Infectious Diseases</i> , 2011, 204, 975-977.	1.9	24
88	Engineering and Preclinical Evaluation of Attenuated Nontyphoidal Salmonella Strains Serving as Live Oral Vaccines and as Reagent Strains. <i>Infection and Immunity</i> , 2011, 79, 4175-4185.	1.0	89
89	Live Attenuated Vaccines: Influenza, Rotavirus and Varicella Zoster Virus. , 2011, , 15-46.		3
90	Immunogenicity of a scalable inactivated rotavirus vaccine in mice. <i>Hum Vaccin</i> , 2011, 7, 248-257.	2.4	9
91	Distribution of Rotavirus Genotypes After Introduction of Rotavirus Vaccines, Rotarix® and RotaTeq®, into the National Immunization Program of Australia. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, S48-S53.	1.1	145
92	Real-world Impact of Rotavirus Vaccination. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, S1-S5.	1.1	217
93	Case-Control Evaluation of the Effectiveness of the G1P[8] Human Rotavirus Vaccine during an Outbreak of Rotavirus G2P[4] Infection in Central Australia. <i>Clinical Infectious Diseases</i> , 2011, 52, 191-199.	2.9	91
94	Whole-genome analysis reveals the complex evolutionary dynamics of Kenyan G2P[4] human rotavirus strains. <i>Journal of General Virology</i> , 2011, 92, 2201-2208.	1.3	23
95	Influence of birth rates and transmission rates on the global seasonality of rotavirus incidence. <i>Journal of the Royal Society Interface</i> , 2011, 8, 1584-1593.	1.5	73
96	Infant Rotavirus Vaccination May Provide Indirect Protection to Older Children and Adults in the United States. <i>Journal of Infectious Diseases</i> , 2011, 204, 980-986.	1.9	178
98	Removing the Age Restrictions for Rotavirus Vaccination: A Benefit-Risk Modeling Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001330.	3.9	63
99	Risk Factors for Death among Children Less than 5 Years Old Hospitalized with Diarrhea in Rural Western Kenya, 2005-2007: A Cohort Study. <i>PLoS Medicine</i> , 2012, 9, e1001256.	3.9	79
100	Rotavirus mortality in India: estimates based on a nationally representative survey of diarrhoeal deaths. <i>Bulletin of the World Health Organization</i> , 2012, 90, 720-727.	1.5	51

#	ARTICLE	IF	CITATIONS
101	Approach to the Patient with Diarrhea and Malabsorption. , 2012, , 895-913.		15
102	Laboratory-Confirmed Rotavirus Disease in Utah Children: Clinical and Economic Impact of Rotavirus Vaccination. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2012, 1, 268-277.	0.6	3
103	Effects of vaccine on rotavirus disease in the pediatric population. <i>Current Opinion in Pediatrics</i> , 2012, 24, 76-84.	1.0	45
104	Vaccines for enteric infections. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 18-23.	1.0	1
105	The Global Enteric Multicenter Study (GEMS) of Diarrheal Disease in Infants and Young Children in Developing Countries: Epidemiologic and Clinical Methods of the Case/Control Study. <i>Clinical Infectious Diseases</i> , 2012, 55, S232-S245.	2.9	300
106	Waging war against rotavirus at home and abroad. <i>Cmaj</i> , 2012, 184, 1011-1011.	0.9	0
107	Practical issues in relation to clinical trials in children in low-income countries: experience from the front line. <i>Archives of Disease in Childhood</i> , 2012, 97, 848-851.	1.0	16
108	Vaccines for preventing rotavirus diarrhoea: vaccines in use. , 2012, , CD008521.		60
109	Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: A randomized, double-blind, placebo-controlled, phase IV study. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 806-812.	1.4	20
110	The promise of immunisation against rotavirus: Figure 1. <i>Archives of Disease in Childhood</i> , 2012, 97, 736-740.	1.0	9
111	Rotavirus. <i>Pediatrics in Review</i> , 2012, 33, 439-447.	0.2	9
112	First Reports of Human Rotavirus G8P[4] Gastroenteritis in the United States. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1118-1121.	1.8	20
113	Rotavirus vaccine: A cost effective control measure for India. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 501-504.	1.4	2
114	Should India launch a national immunisation programme against rotavirus? No. <i>BMJ, The</i> , 2012, 345, e7832-e7832.	3.0	7
115	The Role of Pantone-Valentine Leukocidin in <i>Staphylococcus aureus</i> Musculoskeletal Infections in Children. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 514-518.	1.1	43
116	Postmarketing Surveillance of Intussusception Following Mass Introduction of the Attenuated Human Rotavirus Vaccine in Mexico. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 736-744.	1.1	115
117	Host Response to Probiotics Determined by Nutritional Status of Rotavirus-Infected Neonatal Mice. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 299-307.	0.9	62
118	Efficacy and Immunogenicity of Live-attenuated Human Rotavirus Vaccine in Breast-fed and Formula-fed European Infants. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 509-513.	1.1	41

#	ARTICLE	IF	CITATIONS
119	The effect of routine rotavirus vaccination on healthcare utilization for diarrhea in US children. <i>Immunotherapy</i> , 2012, 4, 269-272.	1.0	0
120	Rotavirus vaccination: a concise review. <i>Clinical Microbiology and Infection</i> , 2012, 18, 57-63.	2.8	93
121	Rotavirus immune responses and correlates of protection. <i>Current Opinion in Virology</i> , 2012, 2, 419-425.	2.6	109
122	Rotavirus vaccination in developing countries. <i>Current Opinion in Virology</i> , 2012, 2, 443-448.	2.6	52
123	Diversity and Relationships of Cocirculating Modern Human Rotaviruses Revealed Using Large-Scale Comparative Genomics. <i>Journal of Virology</i> , 2012, 86, 9148-9162.	1.5	45
124	2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 136-141.	4.6	1,061
125	Updating prevaccination rotavirus-associated mortality. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 94-96.	4.6	0
126	Fulfilling the promise of rotavirus vaccines: how far have we come since licensure?. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 561-570.	4.6	127
127	Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates. <i>Vaccine</i> , 2012, 30, 6121-6126.	1.7	59
128	Monitoring of rotavirus vaccination in Morocco: Establishing the baseline burden of rotavirus disease. <i>Vaccine</i> , 2012, 30, 6515-6520.	1.7	20
129	Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. <i>Vaccine</i> , 2012, 31, 154-158.	1.7	65
130	Identification of common human host genes involved in pathogenesis of different rotavirus strains: An attempt to recognize probable antiviral targets. <i>Virus Research</i> , 2012, 169, 144-153.	1.1	27
131	Rotavirus serotype distribution in northern Brazil trends over a 27 year period pre and post national vaccine introduction. <i>Trials in Vaccinology</i> , 2012, 1, 4-9.	1.2	9
132	Financing vaccinations – The South African experience. <i>Vaccine</i> , 2012, 30, C79-C86.	1.7	14
133	Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience. <i>Trials in Vaccinology</i> , 2012, 1, 10-20.	1.2	8
134	Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality. <i>Expert Review of Vaccines</i> , 2012, 11, 211-220.	2.0	33
135	Modeling the Complexities of Water, Hygiene, and Health in Limpopo Province, South Africa. <i>Environmental Science & Technology</i> , 2012, 46, 13512-13520.	4.6	24
136	Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. <i>BMJ</i> , The, 2012, 345, e4752-e4752.	3.0	124

#	ARTICLE	IF	CITATIONS
137	The pig: a model for human infectious diseases. <i>Trends in Microbiology</i> , 2012, 20, 50-57.	3.5	803
138	A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. <i>Vaccine</i> , 2012, 30, A114-A121.	1.7	48
139	Comparison of two clinical severity scoring systems in two multi-center, developing country rotavirus vaccine trials in Africa and Asia. <i>Vaccine</i> , 2012, 30, A159-A166.	1.7	20
140	Five-year cohort study on the burden of hospitalisation for acute diarrhoeal disease in African HIV-infected and HIV-uninfected children: Potential benefits of rotavirus vaccine. <i>Vaccine</i> , 2012, 30, A173-A178.	1.7	34
141	Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. <i>Vaccine</i> , 2012, 30, A52-A60.	1.7	37
142	Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: A randomized, double-blind, placebo-controlled trial. <i>Vaccine</i> , 2012, 30, A44-A51.	1.7	92
143	Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. <i>Vaccine</i> , 2012, 30, A24-A29.	1.7	66
144	Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh. <i>Vaccine</i> , 2012, 30, A101-A105.	1.7	14
145	Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: Insights for understanding the impact of rotavirus vaccination programs. <i>Vaccine</i> , 2012, 30, A122-A130.	1.7	362
146	Molecular characterization of rotavirus strains detected during a clinical trial of a human rotavirus vaccine in Blantyre, Malawi. <i>Vaccine</i> , 2012, 30, A140-A151.	1.7	16
147	Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: A randomized, double-blind, placebo controlled trial. <i>Vaccine</i> , 2012, 30, A36-A43.	1.7	122
148	Rotavirus vaccines in developing countries: The potential impact, implementation challenges, and remaining questions. <i>Vaccine</i> , 2012, 30, A3-A6.	1.7	33
149	Rotavirus vaccines for children in developing countries: Understanding the science, maximizing the impact, and sustaining the effort. <i>Vaccine</i> , 2012, 30, A1-A2.	1.7	5
150	Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. <i>Vaccine</i> , 2012, 30, A30-A35.	1.7	56
151	Efficacy of the oral pentavalent rotavirus vaccine in Mali. <i>Vaccine</i> , 2012, 30, A71-A78.	1.7	50
153	Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. <i>Vaccine</i> , 2012, 30, A7-A14.	1.7	77
154	Distributional impact of rotavirus vaccination in 25 GAVI countries: Estimating disparities in benefits and cost-effectiveness. <i>Vaccine</i> , 2012, 30, A15-A23.	1.7	53
155	Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. <i>Vaccine</i> , 2012, 30, A79-A85.	1.7	37

#	ARTICLE	IF	CITATIONS
156	Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana. <i>Vaccine</i> , 2012, 30, 2582-2587.	1.7	19
157	Potential impact of accelerating the primary dose of rotavirus vaccine in infants. <i>Vaccine</i> , 2012, 30, 2738-2741.	1.7	2
158	Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population. <i>Vaccine</i> , 2012, 30, 4552-4557.	1.7	56
159	Multiple virus infection alters rotavirus replication and expression of cytokines and Toll-like receptors in intestinal epithelial cells. <i>Virus Research</i> , 2012, 167, 48-55.	1.1	38
160	Human Rotavirus-Specific IgM Memory B Cells Have Differential Cloning Efficiencies and Switch Capacities and Play a Role in Antiviral Immunity <i>In Vivo</i> . <i>Journal of Virology</i> , 2012, 86, 10829-10840.	1.5	27
161	Rotavirus infection and the current status of rotavirus vaccines. <i>Journal of the Formosan Medical Association</i> , 2012, 111, 183-193.	0.8	41
162	Distribution of rotavirus genotypes after vaccine introduction in the Triângulo Mineiro region of Brazil: 4-Year follow-up study. <i>Journal of Clinical Virology</i> , 2012, 55, 67-71.	1.6	29
163	Investigation of porcine circovirus contamination in human vaccines. <i>Biologicals</i> , 2012, 40, 270-277.	0.5	38
164	Vaccines against mucosal infections. <i>Current Opinion in Immunology</i> , 2012, 24, 343-353.	2.4	132
165	Human rotavirus vaccine Rotarix [®] provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. <i>BMC Infectious Diseases</i> , 2012, 12, 213.	1.3	117
166	Burden of acute gastroenteritis among children younger than 5 years of age – a survey among parents in the United Arab Emirates. <i>BMC Pediatrics</i> , 2012, 12, 74.	0.7	25
167	Impact of rotavirus vaccines on rotavirus disease. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 547-561.	2.0	12
168	Key statements of IAPCOI and IAP Immunization Timetable for year 2012. <i>Pediatric Infectious Disease</i> , 2012, 4, 112-124.	0.1	0
169	Rotavirus in diarrheal children in rural Burkina Faso: High prevalence of genotype G6P[6]. <i>Infection, Genetics and Evolution</i> , 2012, 12, 1892-1898.	1.0	26
170	Progress and hurdles in the development of vaccines against enterotoxigenic <i>Escherichia coli</i> in humans. <i>Expert Review of Vaccines</i> , 2012, 11, 677-694.	2.0	100
171	Rotavirus Infection. <i>Advances in Pediatrics</i> , 2012, 59, 47-74.	0.5	22
172	Enteric viruses in wastewaters: an interesting approach to evaluate the potential impact of rotavirus vaccination on viral circulation. <i>Expert Review of Vaccines</i> , 2012, 11, 419-422.	2.0	6
173	Vaccines for preventing rotavirus diarrhoea: vaccines in use. , 2012, 11, CD008521.		201

#	ARTICLE	IF	CITATIONS
174	Rotavirus vaccination within the South African Expanded Programme on Immunisation. <i>Vaccine</i> , 2012, 30, C14-C20.	1.7	27
175	Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix®, [®]) in the Prevention of Rotavirus Gastroenteritis in Developing Countries. <i>Paediatric Drugs</i> , 2012, 14, 429-433.	1.3	0
177	OPV for children who have received IPV. <i>Indian Pediatrics</i> , 2012, 49, 998-999.	0.2	0
178	Consensus recommendations on immunization and IAP immunization timetable 2012. <i>Indian Pediatrics</i> , 2012, 49, 549-564.	0.2	40
179	In Vitro Neutralisation of Rotavirus Infection by Two Broadly Specific Recombinant Monovalent Llama-Derived Antibody Fragments. <i>PLoS ONE</i> , 2012, 7, e32949.	1.1	31
180	Individual and Contextual Factors Associated with Low Childhood Immunisation Coverage in Sub-Saharan Africa: A Multilevel Analysis. <i>PLoS ONE</i> , 2012, 7, e37905.	1.1	171
181	A Cost Effectiveness and Capacity Analysis for the Introduction of Universal Rotavirus Vaccination in Kenya: Comparison between Rotarix and RotaTaq Vaccines. <i>PLoS ONE</i> , 2012, 7, e47511.	1.1	31
182	Rotaviruses, Noroviruses, and Other Gastrointestinal Viruses. , 2012, , 2144-2147.		4
183	Oral live attenuated human rotavirus vaccine (Rotarix™) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2012, 107, 846-853.	0.8	23
184	Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. <i>Medical Journal of Australia</i> , 2012, 197, 453-457.	0.8	74
185	Rotavirus vaccination and herd immunity: an evidence-based review. <i>Pediatric Health, Medicine and Therapeutics</i> , 2012, , 25.	0.7	0
186	South African HIV-1 vaccine candidates – the journey from the bench to clinical trials. <i>South African Medical Journal</i> , 2012, 102, 452.	0.2	9
189	Vaccine-derived NSP2 segment in rotaviruses from vaccinated children with gastroenteritis in Nicaragua. <i>Infection, Genetics and Evolution</i> , 2012, 12, 1282-1294.	1.0	67
190	Recent progress in mucosal vaccine development: potential and limitations. <i>Nature Reviews Immunology</i> , 2012, 12, 592-605.	10.6	627
191	Phylogenetic and computational structural analysis of VP7 gene of group a human rotavirus G1P[8] strains obtained in Sapporo, Japan from 1987 to 2000. <i>Journal of Medical Virology</i> , 2012, 84, 832-838.	2.5	15
192	Epidemiology and prospects for prevention of rotavirus disease in India. <i>Indian Pediatrics</i> , 2012, 49, 467-474.	0.2	43
193	Antigenemia, RNAemia, and innate immunity in children with acute rotavirus diarrhea. <i>FEMS Immunology and Medical Microbiology</i> , 2012, 64, 382-391.	2.7	26
194	The Role of Prolonged Viral Gastrointestinal Infections in the Development of Immunodeficiency-Related Enteropathy. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 79-91.	2.9	9

#	ARTICLE	IF	CITATIONS
195	Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch. <i>Vaccine</i> , 2013, 31, 3396-3402.	1.7	77
196	Oral Vaccination: Attenuated and Gene-Based. , 2013, , 81-104.		0
197	New concepts in diagnostics for infectious diarrhea. <i>Mucosal Immunology</i> , 2013, 6, 876-885.	2.7	54
199	Community Diarrhea Incidence Before and After Rotavirus Vaccine Introduction in Nicaragua. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 246-250.	0.6	16
201	Efficacy, Immunogenicity, and Safety of Two Doses of a Tetravalent Rotavirus Vaccine RRV-TV in Ghana With the First Dose Administered During the Neonatal Period. <i>Journal of Infectious Diseases</i> , 2013, 208, 423-431.	1.9	55
202	Anti-Rotavirus Protein Reduces Stool Output in Infants With Diarrhea: A Randomized Placebo-Controlled Trial. <i>Gastroenterology</i> , 2013, 145, 740-748.e8.	0.6	52
203	Viral gastroenteritis. <i>Medicine</i> , 2013, 41, 700-704.	0.2	5
204	A Systematic Review of Anti-Rotavirus Serum IgA Antibody Titer as a Potential Correlate of Rotavirus Vaccine Efficacy. <i>Journal of Infectious Diseases</i> , 2013, 208, 284-294.	1.9	150
205	Rotavirus genotypes associated with childhood severe acute diarrhoea in southern Ghana: a cross-sectional study. <i>Virology Journal</i> , 2013, 10, 287.	1.4	34
206	Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus. <i>BMC Public Health</i> , 2013, 13, S11.	1.2	34
207	Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years – India, 2013 and updates on immunization. <i>Indian Pediatrics</i> , 2013, 50, 1095-1108.	0.2	39
208	Rotavirus vaccines. , 2013, , 669-687.		3
209	Diversity of rotavirus strains circulating in children under 5 years of age admitted to hospital for acute gastroenteritis in morocco, june 2006 to may 2009. <i>Journal of Medical Virology</i> , 2013, 85, 354-362.	2.5	26
210	Vaccines for low-income countries. <i>Seminars in Immunology</i> , 2013, 25, 114-123.	2.7	31
211	Phase I trial of RV3-BB rotavirus vaccine: A human neonatal rotavirus vaccine. <i>Vaccine</i> , 2013, 31, 2610-2616.	1.7	33
212	Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis. <i>Vaccine</i> , 2013, 31, 4902-4910.	1.7	88
213	Consensus sequence determination and elucidation of the evolutionary history of a rotavirus Wa variant reveal a close relationship to various Wa variants derived from the original Wa strain. <i>Infection, Genetics and Evolution</i> , 2013, 20, 276-283.	1.0	6
214	Progress and pitfalls in Shigella vaccine research. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 245-255.	8.2	117

#	ARTICLE	IF	CITATIONS
215	Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease. <i>Expert Review of Vaccines</i> , 2013, 12, 169-181.	2.0	38
216	Rotavirus. , 2013, , 276-279.		0
217	One Year Survey of Human Rotavirus Strains Suggests the Emergence of Genotype G12 in Cameroon. <i>Journal of Medical Virology</i> , 2013, 85, 1485-1490.	2.5	35
218	The status of live viral vaccination in early life. <i>Vaccine</i> , 2013, 31, 2531-2537.	1.7	11
219	Rotavirus genotype distribution during the pre-vaccine period in Bolivia: 2007-2008. <i>International Journal of Infectious Diseases</i> , 2013, 17, e762-e767.	1.5	12
221	Vaccination of human immunodeficiency virus-infected persons. , 2013, , 1257-1269.		1
222	Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study. <i>BMJ, The</i> , 2013, 346, f3726-f3726.	3.0	70
223	Surveillance of rotavirus gastro-enteritis in children in Blantyre, Malawi. <i>Paediatrics and International Child Health</i> , 2013, 33, 42-45.	0.3	7
224	Effect of Rotavirus Vaccine on Diarrhea Mortality in Different Socioeconomic Regions of Mexico. <i>Pediatrics</i> , 2013, 131, e1115-e1120.	1.0	56
225	The Rotavirus Experience in Mexico: Discovery to Control. <i>Clinical Infectious Diseases</i> , 2013, 56, 548-551.	2.9	8
226	Prevalence of Gastrointestinal Pathogens in Developed and Developing Countries: Systematic Review and Meta-Analysis. <i>Journal of Public Health Research</i> , 2013, 2, jphr.2013.e9.	0.5	111
227	Role of Antidiarrhoeal Drugs as Adjunctive Therapies for Acute Diarrhoea in Children. <i>International Journal of Pediatrics (United Kingdom)</i> , 2013, 2013, 1-14.	0.2	32
228	Detection of unusual G6 rotavirus strains in Italian children with diarrhoea during the 2011 surveillance season. <i>Journal of Medical Virology</i> , 2013, 85, 1860-1869.	2.5	14
229	Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, Rotarix. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2398-2408.	1.4	42
230	Impact of rotavirus vaccination in Australian children below 5 years of age. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1617-1625.	1.4	23
231	Diagnosis, management, and prevention of rotavirus gastroenteritis in children. <i>BMJ, The</i> , 2013, 347, f7204-f7204.	3.0	98
232	Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity?. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1634-1637.	1.4	38
233	The VP8* Domain of Neonatal Rotavirus Strain G10P[11] Binds to Type II Precursor Glycans. <i>Journal of Virology</i> , 2013, 87, 7255-7264.	1.5	74

#	ARTICLE	IF	CITATIONS
234	Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1638-1642.	1.4	8
235	Etiology of Diarrhea in Bangladeshi Infants in the First Year of Life Analyzed Using Molecular Methods. <i>Journal of Infectious Diseases</i> , 2013, 208, 1794-1802.	1.9	164
236	Impact of Rotavirus Vaccine on Childhood Diarrheal Hospitalization After Introduction Into the South African Public Immunization Program. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 1359-1364.	1.1	70
237	Understanding the contribution of common childhood illnesses and opportunistic infections to morbidity and mortality in children living with HIV in resource-limited settings. <i>Aids</i> , 2013, 27, S159-S167.	1.0	10
239	Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. <i>Journal of Clinical Investigation</i> , 2013, 123, 3829-3838.	3.9	73
240	Rotavirus gastroenteritis in children under 5 years in the Kingdom of Bahrain: hospital-based surveillance. <i>Clinical Epidemiology</i> , 2013, 5, 269.	1.5	15
241	Nosocomial rotavirus gastroenterocolitis in a large tertiary paediatric hospital in Warsaw, 2006-2010. <i>Archives of Medical Science</i> , 2013, 3, 493-498.	0.4	8
242	The Infant with Acute Diarrhoea. , 2013, , 32-34.		0
243	Reducing mortality from childhood pneumonia and diarrhoea: The leading priority is also the greatest opportunity. <i>Journal of Global Health</i> , 2013, 3, 010101.	1.2	108
244	Experimental Pathways towards Developing a Rotavirus Reverse Genetics System: Synthetic Full Length Rotavirus ssRNAs Are Neither Infectious nor Translated in Permissive Cells. <i>PLoS ONE</i> , 2013, 8, e74328.	1.1	26
245	Rotavirus Surveillance in Kisangani, the Democratic Republic of the Congo, Reveals a High Number of Unusual Genotypes and Gene Segments of Animal Origin in Non-Vaccinated Symptomatic Children. <i>PLoS ONE</i> , 2014, 9, e100953.	1.1	43
246	Co-Expression of Anti-Rotavirus Proteins (Llama VHH Antibody Fragments) in <i>Lactobacillus</i> : Development and Functionality of Vectors Containing Two Expression Cassettes in Tandem. <i>PLoS ONE</i> , 2014, 9, e96409.	1.1	22
247	Genetic Diversity of Circulating Rotavirus Strains in Tanzania Prior to the Introduction of Vaccination. <i>PLoS ONE</i> , 2014, 9, e97562.	1.1	36
248	Predominance of Norovirus and Sapovirus in Nicaragua after Implementation of Universal Rotavirus Vaccination. <i>PLoS ONE</i> , 2014, 9, e98201.	1.1	142
249	Sentinel Hospital-Based Surveillance for Assessment of Burden of Rotavirus Gastroenteritis in Children in Pakistan. <i>PLoS ONE</i> , 2014, 9, e108221.	1.1	21
250	Effectiveness of pneumococcal conjugate vaccine and rotavirus vaccine introduction into the South African public immunisation programme. <i>South African Medical Journal</i> , 2014, 104, 228.	0.2	26
251	Ratification of rapid rotavirus diagnostic test strips. <i>Southern African Journal of Infectious Diseases</i> , 2014, 29, 91-94.	0.3	1
253	Re-thinking the functions of IgA ⁺ plasma cells. <i>Gut Microbes</i> , 2014, 5, 652-662.	4.3	95

#	ARTICLE	IF	CITATIONS
254	Closing the Global Immunization Gap: Delivery of Lifesaving Vaccines Through Innovation and Technology. <i>Pediatrics in Review</i> , 2014, 35, e32-e40.	0.2	6
255	Recent advances in oral vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1309-1318.	1.4	64
256	The human rotavirus vaccine Rotarix [®] in infants. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 19-24.	1.4	17
257	Detection of PCV-2 DNA in stool samples from infants vaccinated with RotaTeq [®] . <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 25-32.	1.4	20
258	Mucosal vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2175-2187.	1.4	49
259	Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 505-511.	1.4	52
260	Probiotics and virulent human rotavirus modulate the transplanted human gut microbiota in gnotobiotic pigs. <i>Gut Pathogens</i> , 2014, 6, 39.	1.6	49
261	Early exposure of infants to natural rotavirus infection: a review of studies with human rotavirus vaccine RIX4414. <i>BMC Pediatrics</i> , 2014, 14, 295.	0.7	19
262	Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3659-3671.	1.4	69
263	Characterization of a G1P[8] rotavirus causing an outbreak of gastroenteritis in the Northern Territory, Australia, in the vaccine era. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-6.	3.0	12
264	Diarrhoea-related hospitalizations in children before and after implementation of monovalent rotavirus vaccination in Mexico. <i>Bulletin of the World Health Organization</i> , 2014, 92, 117-125.	1.5	21
265	Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. <i>Bulletin of the World Health Organization</i> , 2014, 92, 238-245.	1.5	81
266	Impact of Different Dosing Schedules on the Immunogenicity of the Human Rotavirus Vaccine in Infants in Pakistan: A Randomized Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1772-1779.	1.9	41
267	Influence of Enteric Infections on Response to Oral Poliovirus Vaccine: A Systematic Review and Meta-analysis. <i>Journal of Infectious Diseases</i> , 2014, 210, 853-864.	1.9	63
268	Hospital-based surveillance of rotavirus gastroenteritis among children under 5 years of age in the Republic of Ivory Coast: a cross-sectional study. <i>BMJ Open</i> , 2014, 4, e003269.	0.8	13
269	Rotavirus Surveillance in Urban and Rural Areas of Niger, April 2010–March 2012. <i>Emerging Infectious Diseases</i> , 2014, 20, 573-580.	2.0	24
270	Rotavirus vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1436-1448.	1.4	77
271	Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1096-1104.	4.6	119

#	ARTICLE	IF	CITATIONS
272	Mass prophylaxis of tuberculosis through social protection. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1032-1034.	4.6	4
273	Intussusception following rotavirus vaccination: an updated review of the available evidence. <i>Expert Review of Vaccines</i> , 2014, 13, 1339-1348.	2.0	41
274	Sustaining rotavirus vaccination in Africa: measuring vaccine effectiveness. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1031-1032.	4.6	0
275	Differences in lineage replacement dynamics of G1 and G2 rotavirus strains versus G9 strain over a period of 22years in Bangladesh. <i>Infection, Genetics and Evolution</i> , 2014, 28, 214-222.	1.0	16
276	Longitudinal analysis of VP7 gene of group A human rotavirus G2P[4] strains circulating in the pre-vaccine era in Sapporo, Japan from 1991 to 2011. <i>Microbiology and Immunology</i> , 2014, 58, 540-544.	0.7	0
277	Characterization of the NSP4 gene of group A human rotavirus G1P[8] strains circulating in Sapporo, Japan from 1987 to 2000. <i>Journal of Medical Virology</i> , 2014, 86, 354-359.	2.5	9
278	Adjuvant potential of low dose all-trans retinoic acid during oral typhoid vaccination in Zambian men. <i>Clinical and Experimental Immunology</i> , 2014, 175, 468-475.	1.1	15
279	Severe Acute Rotavirus Gastroenteritis in Children Less Than 5 Years in Southern Ghana. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, S9-S13.	1.1	16
280	High Index of Suspicion of Intussusception in an 8-month South African Child. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, S104-S106.	1.1	0
281	Baseline Burden of Rotavirus Disease in Sudan to Monitor the Impact of Vaccination. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, S23-S27.	1.1	20
282	High Burden of Rotavirus Gastroenteritis in Young Children in Rural Western Kenya, 2010–2011. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, S34-S40.	1.1	16
283	Rotavirus Genotypes Associated with Acute Diarrhea in Egyptian Infants. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, S62-S68.	1.1	16
284	Rotavirus G and P Types Circulating in the Eastern Region of Kenya. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, S85-S88.	1.1	37
285	Preparing for the Scale-up of Rotavirus Vaccine Introduction in Africa. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, S1-S5.	1.1	19
286	Can Routinely Collected National Data on Childhood Morbidity and Mortality from Diarrhea be Used to Monitor Health Impact of Rotavirus Vaccination in Africa?. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, S89-S93.	1.1	7
287	Use of <i>Vibrio cholerae</i> Vaccine in an Outbreak in Guinea. <i>New England Journal of Medicine</i> , 2014, 370, 2111-2120.	13.9	138
288	Lactobacilli and Bifidobacteria enhance mucosal B cell responses and differentially modulate systemic antibody responses to an oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model. <i>Gut Microbes</i> , 2014, 5, 639-651.	4.3	89
289	Maximizing protection from use of oral cholera vaccines in developing country settings. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1457-1465.	1.4	16

#	ARTICLE	IF	CITATIONS
290	Use of Population-based Surveillance to Determine the Incidence of Rotavirus Gastroenteritis in an Urban Slum and a Rural Setting in Kenya. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, S54-S61.	1.1	10
291	Three-Combination Probiotics Therapy in Children With Salmonella and Rotavirus Gastroenteritis. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 37-42.	1.1	40
292	Modeling the sustainability of a ceramic water filter intervention. <i>Water Research</i> , 2014, 49, 286-299.	5.3	40
293	ZakaÅ¼enia rotawirusowe – aktualne zalecenia i propozycje dotyczÄ...ce zapobiegania. <i>Pediatrica Polska</i> , 2014, 89, 176-184.	0.1	0
294	Team science and the creation of a novel rotavirus vaccine in India: a new framework for vaccine development. <i>Lancet, The</i> , 2014, 383, 2180-2183.	6.3	22
295	Report of the 7th African Rotavirus Symposium, Cape Town, South Africa, 8th November 2012. <i>Vaccine</i> , 2014, 32, 6336-6341.	1.7	2
296	Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2014, 383, 2136-2143.	6.3	261
297	Budget constraint and vaccine dosing: a mathematical modelling exercise. <i>Cost Effectiveness and Resource Allocation</i> , 2014, 12, 3.	0.6	12
298	Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. <i>Vaccine</i> , 2014, 32, 3133-3138.	1.7	35
299	Molecular analysis of group A rotaviruses detected in adults and adolescents with severe acute gastroenteritis in Italy in 2012. <i>Journal of Medical Virology</i> , 2014, 86, 1073-1082.	2.5	13
300	Rotavirus vaccines: Successes and challenges. <i>Journal of Infection</i> , 2014, 68, S9-S18.	1.7	76
301	Engineered <i>Lactobacillus rhamnosus</i> GG expressing IgG-binding domains of protein G: Capture of hyperimmune bovine colostrum antibodies and protection against diarrhea in a mouse pup rotavirus infection model. <i>Vaccine</i> , 2014, 32, 470-477.	1.7	20
302	Molecular characterization of human G8P[4] rotavirus strains in Italy: Proposal of a more complete subclassification of the G8 genotype in three major lineages. <i>Infection, Genetics and Evolution</i> , 2014, 21, 129-133.	1.0	16
303	Molecular surveillance of rotavirus strains circulating in YaoundÃ©, Cameroon, September 2007–December 2012. <i>Infection, Genetics and Evolution</i> , 2014, 28, 470-475.	1.0	19
304	The MAL-ED Study: A Multinational and Multidisciplinary Approach to Understand the Relationship Between Enteric Pathogens, Malnutrition, Gut Physiology, Physical Growth, Cognitive Development, and Immune Responses in Infants and Children Up to 2 Years of Age in Resource-Poor Environments. <i>Clinical Infectious Diseases</i> , 2014, 59, S193-S206.	2.9	306
305	Whole genomic analysis of human G12P[6] and G12P[8] rotavirus strains that have emerged in Kenya: Identification of porcine-like NSP4 genes. <i>Infection, Genetics and Evolution</i> , 2014, 27, 277-293.	1.0	33
306	Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines. <i>Experimental and Molecular Medicine</i> , 2014, 46, e85-e85.	3.2	91
307	Both Lewis and Secretor Status Mediate Susceptibility to Rotavirus Infections in a Rotavirus Genotype–Dependent Manner. <i>Clinical Infectious Diseases</i> , 2014, 59, 1567-1573.	2.9	192

#	ARTICLE	IF	CITATIONS
308	The use of a placebo in vaccine trials. <i>Lancet, The</i> , 2014, 383, 2101-2102.	6.3	2
309	Development of an enzyme-linked immunospot assay for determination of rotavirus infectivity. <i>Journal of Virological Methods</i> , 2014, 209, 7-14.	1.0	15
310	Rotaviruses. <i>Virus Research</i> , 2014, 190, 75-96.	1.1	298
311	Rotavirus disease and vaccines in India: A tremendous public health opportunity. <i>Vaccine</i> , 2014, 32, vii-xii.	1.7	2
312	Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India. <i>Vaccine</i> , 2014, 32, A104-A109.	1.7	24
313	Immunogenicity of a three dose and five dose oral human rotavirus vaccine (RIX4414) schedule in south Indian infants. <i>Vaccine</i> , 2014, 32, A129-A133.	1.7	33
314	A proposed framework for evaluating and comparing efficacy estimates in clinical trials of new rotavirus vaccines. <i>Vaccine</i> , 2014, 32, A179-A184.	1.7	11
315	Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants. <i>Vaccine</i> , 2014, 32, A134-A139.	1.7	69
316	Safety of Vaccines Used for Routine Immunization of US Children: A Systematic Review. <i>Pediatrics</i> , 2014, 134, 325-337.	1.0	192
317	Insights from global data for use of rotavirus vaccines in India. <i>Vaccine</i> , 2014, 32, A171-A178.	1.7	5
318	Inclusion of a universal tetanus toxoid CD4+ T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus VP8* subunit parenteral vaccines. <i>Vaccine</i> , 2014, 32, 4420-4427.	1.7	45
319	Synthesizing evidences for policy translation: A public health discourse on rotavirus vaccine in India. <i>Vaccine</i> , 2014, 32, A162-A170.	1.7	8
320	Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2014, 14, 847-856.	4.6	182
321	New approaches in oral rotavirus vaccines. <i>Critical Reviews in Microbiology</i> , 2014, 42, 1-11.	2.7	8
322	Decline in severe diarrhea hospitalizations after the introduction of rotavirus vaccination in Ghana: a prevalence study. <i>BMC Infectious Diseases</i> , 2014, 14, 431.	1.3	32
323	Rotavirus Vaccines in Routine Use. <i>Clinical Infectious Diseases</i> , 2014, 59, 1291-1301.	2.9	85
324	Human and bovine rotavirus strain antigens for evaluation of immunogenicity in a randomized, double-blind, placebo-controlled trial of a single dose live attenuated tetravalent, bovine-human-reassortant, oral rotavirus vaccine in Indian adults. <i>Vaccine</i> , 2014, 32, 3094-3100.	1.7	13
325	Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. <i>Vaccine</i> , 2014, 32, 651-656.	1.7	66

#	ARTICLE	IF	CITATIONS
326	Impact of emergency department probiotic treatment of pediatric gastroenteritis: study protocol for the PROGUT (Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment) randomized controlled trial. <i>Trials</i> , 2014, 15, 170.	0.7	23
327	Oral polio vaccine response in breast fed infants with malnutrition and diarrhea. <i>Vaccine</i> , 2014, 32, 478-482.	1.7	59
328	Prevalence of rotavirus infection in children below two years presenting with diarrhea. <i>Medical Journal Armed Forces India</i> , 2014, 70, 116-119.	0.3	18
329	Use of vaccines as probes to define disease burden. <i>Lancet, The</i> , 2014, 383, 1762-1770.	6.3	101
330	Nationwide survey of rotavirus-associated encephalopathy and sudden unexpected death in Japan. <i>Brain and Development</i> , 2014, 36, 601-607.	0.6	23
331	Antibiotic Treatment Suppresses Rotavirus Infection and Enhances Specific Humoral Immunity. <i>Journal of Infectious Diseases</i> , 2014, 210, 171-182.	1.9	182
332	2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. <i>Clinical Infectious Diseases</i> , 2014, 58, e44-e100.	2.9	910
333	Report of the Third European Expert Meeting on Rotavirus Vaccination: Progress in rotavirus universal mass vaccination in Europe. <i>Vaccine</i> , 2014, 32, 4243-4248.	1.7	8
334	116E rotavirus vaccine development: a successful alliance. <i>Lancet, The</i> , 2014, 383, 2106-2107.	6.3	4
335	Effectiveness of rotavirus vaccine against hospitalized rotavirus diarrhea: A case-control study. <i>Vaccine</i> , 2014, 32, 2740-2747.	1.7	40
337	Rotavirus and Other Viral Diarrhoea. , 2014, , 207-214.e3.		1
338	Live viral vaccines in immunocompromised patients. <i>Future Virology</i> , 2014, 9, 161-171.	0.9	6
339	Immunization equity. <i>Vaccine</i> , 2015, 33, D72-D77.	1.7	12
340	Biological challenges to effective vaccines in the developing world. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140138.	1.8	23
341	Controlling Rotavirus-associated diarrhea: Could single-domain antibody fragments make the difference?. <i>Revista Argentina De Microbiologia</i> , 2015, 47, 368-379.	0.4	9
342	European Society for Paediatric Infectious Diseases Consensus Recommendations for Rotavirus Vaccination in Europe. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 635-643.	1.1	54
343	Engineering and expression of a human rotavirus candidate vaccine in <i>Nicotiana benthamiana</i> . <i>Virology Journal</i> , 2015, 12, 205.	1.4	21
344	Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e176-e184.	1.1	8

#	ARTICLE	IF	CITATIONS
345	Case Control Study of Rotavirus Vaccine Effectiveness in Portugal During 6 Years of Private Market Use. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 509-512.	1.1	21
346	Influence of Epicuticular Physicochemical Properties on Porcine Rotavirus Adsorption to 24 Leafy Green Vegetables and Tomatoes. <i>PLoS ONE</i> , 2015, 10, e0132841.	1.1	25
347	Investigation of Stilbenoids as Potential Therapeutic Agents for Rotavirus Gastroenteritis. <i>Advances in Virology</i> , 2015, 2015, 1-10.	0.5	20
348	Comparison of Vesikari and Clark scales regarding the definition of severe rotavirus gastroenteritis in children. <i>Infectious Diseases</i> , 2015, 47, 332-337.	1.4	11
349	Vaccines against Bacterial Enteric Infections. , 2015, , 1047-1082.		7
350	Acute Gastroenteritis Viruses. , 2015, , 1083-1103.		0
351	Passive Immunization. , 2015, , 1403-1434.		19
352	Cost-effectiveness of live oral attenuated human rotavirus vaccine in Tanzania. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 7.	0.6	18
353	Vaccines against enteric infections for the developing world. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20150142.	1.8	53
354	Rotavirus VP6 preparations as a non-replicating vaccine candidates. <i>Vaccine</i> , 2015, 33, 3281-3287.	1.7	20
355	Potential for use of retinoic acid as an oral vaccine adjuvant. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140145.	1.8	16
356	Probiotics, antibiotics and the immune responses to vaccines. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140144.	1.8	51
357	Use of Surveillance Data to Assess the Impact of Vaccination on Circulating Rotavirus Strains. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, e90-e92.	0.6	1
358	Health gains and financial risk protection: an extended cost-effectiveness analysis of treatment and prevention of diarrhoea in Ethiopia. <i>BMJ Open</i> , 2015, 5, e006402-e006402.	0.8	22
359	116E rotavirus vaccine may have less impact in India than projected. <i>Vaccine</i> , 2015, 33, 7142.	1.7	1
360	Chitosan-based mucosal adjuvants: Sunrise on the ocean. <i>Vaccine</i> , 2015, 33, 5997-6010.	1.7	76
361	Value of Post-Licensure Data on Benefits and Risks of Vaccination to Inform Vaccine Policy. <i>American Journal of Preventive Medicine</i> , 2015, 49, S377-S382.	1.6	10
362	Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. <i>The Lancet Global Health</i> , 2015, 3, e288-e296.	2.9	85

#	ARTICLE	IF	CITATIONS
363	Immunization Equity. American Journal of Preventive Medicine, 2015, 49, S399-S405.	1.6	15
364	Rotavirus vaccines in developing countries: issues and future considerations. Future Virology, 2015, 10, 663-666.	0.9	2
365	Comparison of impact and cost-effectiveness of rotavirus supplementary and routine immunization in a complex humanitarian emergency, Somali case study. Conflict and Health, 2015, 9, 5.	1.0	11
366	Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study. Lancet Infectious Diseases, The, 2015, 15, 422-428.	4.6	151
367	Conquering rotavirus: From discovery to global vaccine implementation. Journal of Paediatrics and Child Health, 2015, 51, 34-39.	0.4	11
368	Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine. Archives of Virology, 2015, 160, 2075-2078.	0.9	43
369	Human rotavirus vaccine (<i>Rotarix</i>): focus on effectiveness and impact 6 years after first introduction in Africa. Expert Review of Vaccines, 2015, 14, 1099-1112.	2.0	18
370	An Exopolysaccharide-Deficient Mutant of Lactobacillus rhamnosus GG Efficiently Displays a Protective Llama Antibody Fragment against Rotavirus on Its Surface. Applied and Environmental Microbiology, 2015, 81, 5784-5793.	1.4	24
371	Tandem truncated rotavirus VP8* subunit protein with T cell epitope as non-replicating parenteral vaccine is highly immunogenic. Human Vaccines and Immunotherapeutics, 2015, 11, 2483-2489.	1.4	15
372	Impact of vaccination on the molecular epidemiology and evolution of group A rotaviruses in Latin America and factors affecting vaccine efficacy. Infection, Genetics and Evolution, 2015, 34, 106-113.	1.0	13
373	Value of post-licensure data on benefits and risks of vaccination to inform vaccine policy: The example of rotavirus vaccines. Vaccine, 2015, 33, D55-D59.	1.7	23
374	Human rotavirus group a serotypes causing gastroenteritis in children less than 5 years and HIV-infected adults in Viwandani Slum, Nairobi. Ethiopian Journal of Health Sciences, 2015, 25, 39.	0.2	9
375	Rotavirus vaccine effectiveness in Latin American and Caribbean countries: A systematic review and meta-analysis. Vaccine, 2015, 33, A248-A254.	1.7	34
376	Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis. Vaccine, 2015, 33, A119-A125.	1.7	15
377	Cost-effectiveness of rotavirus vaccination in Kenya and Uganda. Vaccine, 2015, 33, A109-A118.	1.7	37
378	High rate of detection of G8P[6] rotavirus in children with acute gastroenteritis in São Tomé and Príncipe. Archives of Virology, 2015, 160, 423-428.	0.9	12
379	Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate. Vaccine, 2015, 33, 2606-2613.	1.7	24
380	Effect of monovalent rotavirus vaccine on rotavirus disease burden and circulating rotavirus strains among children in Morocco. Journal of Medical Virology, 2015, 87, 944-953.	2.5	13

#	ARTICLE	IF	CITATIONS
381	Methods and challenges in measuring the impact of national pneumococcal and rotavirus vaccine introduction on morbidity and mortality in Malawi. <i>Vaccine</i> , 2015, 33, 2637-2645.	1.7	20
382	Unexpected spreading of G12P[8] rotavirus strains among young children in a small area of central Italy. <i>Journal of Medical Virology</i> , 2015, 87, 1292-1302.	2.5	30
383	Whole genome detection of rotavirus mixed infections in human, porcine and bovine samples co-infected with various rotavirus strains collected from sub-Saharan Africa. <i>Infection, Genetics and Evolution</i> , 2015, 31, 321-334.	1.0	42
384	Infectious diarrhoea. <i>Medicine</i> , 2015, 43, 253-258.	0.2	7
385	Reducing diarrhoea deaths in South Africa: costs and effects of scaling up essential interventions to prevent and treat diarrhoea in under-five children. <i>BMC Public Health</i> , 2015, 15, 394.	1.2	35
386	Current status of rotavirus vaccines. <i>World Journal of Pediatrics</i> , 2015, 11, 300-308.	0.8	14
387	Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1389-1397.	4.6	70
388	Rotavirus Infection. <i>Infectious Disease Clinics of North America</i> , 2015, 29, 617-635.	1.9	35
389	Immunogenicity and efficacy in mice of an adenovirus-based bicistronic rotavirus vaccine expressing NSP4 and VP7. <i>Virus Research</i> , 2015, 210, 298-307.	1.1	9
390	Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection. <i>Vaccine</i> , 2015, 33, 6604-6610.	1.7	18
391	Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. <i>Mucosal Immunology</i> , 2015, 8, 1-17.	2.7	118
392	Formation of self-assembled triple-layered rotavirus-like particles (tRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. <i>Journal of Medical Virology</i> , 2015, 87, 102-111.	2.5	15
393	Rotavirus Vaccines and Vaccination. , 2016, , 301-328.		2
394	The effectiveness of rotavirus vaccine in preventing acute gastroenteritis during rotavirus seasons among Polish children. <i>Archives of Medical Science</i> , 2016, 3, 614-620.	0.4	3
395	Rotaviruses. , 2016, , 853-872.		0
397	Epidémiologie moléculaire du rotavirus du groupe A associée aux gastroentérites chez les enfants de moins de 5 ans dans la ville de Yaoundé (Cameroun). <i>International Journal of Biological and Chemical Sciences</i> , 2016, 9, 2561.	0.1	4
398	Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles. <i>Journal of Immunology Research</i> , 2016, 2016, 1-13.	0.9	29
399	The impact of rotavirus vaccination on emergency department visits and hospital admissions for acute diarrhea in children under 5 years. <i>Revista Da Associação Médica Brasileira</i> , 2016, 62, 506-512.	0.3	6

#	ARTICLE	IF	CITATIONS
400	Rotavirus Vaccines. , 2016, , 265-279.		2
401	Stress Response and Translation Control in Rotavirus Infection. <i>Viruses</i> , 2016, 8, 162.	1.5	12
402	Findings from a comprehensive diarrhoea prevention and treatment programme in Lusaka, Zambia. <i>BMC Public Health</i> , 2016, 16, 475.	1.2	12
403	Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants. <i>PLoS ONE</i> , 2016, 11, e0150100.	1.1	57
404	Decline in Emergency Department Visits for Acute Gastroenteritis Among Children in 10 US States After Implementation of Rotavirus Vaccination, 2003 to 2013. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 782-786.	1.1	17
405	Population Impact and Effectiveness of Monovalent Rotavirus Vaccination in Urban Malawian Children 3 Years After Vaccine Introduction: Ecological and Case-Control Analyses. <i>Clinical Infectious Diseases</i> , 2016, 62, S213-S219.	2.9	101
406	Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate. <i>Vaccine</i> , 2016, 34, 2397-2401.	1.7	18
407	Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward. <i>Clinical Infectious Diseases</i> , 2016, 62, S91-S95.	2.9	83
408	Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patientâ€™Level Costing Data. <i>Clinical Infectious Diseases</i> , 2016, 62, S220-S228.	2.9	34
409	Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines. <i>Clinical Microbiology and Infection</i> , 2016, 22, S128-S135.	2.8	19
410	Time-trend analysis of the impact of universal rotavirus vaccination in Brazil. <i>Indian Pediatrics</i> , 2016, 53, 645-650.	0.2	0
411	Molecular characterization of two rare human G8P[14] rotavirus strains, detected in Italy in 2012. <i>Infection, Genetics and Evolution</i> , 2016, 44, 303-312.	1.0	10
412	Diarrhoea in children under five years of age in South Africa (1997â€™2014). <i>Tropical Medicine and International Health</i> , 2016, 21, 1060-1070.	1.0	12
413	Developing an Inactivated Rotavirus Vaccine and Evaluating the Immunogenicity Against a Commercially Available Attenuated Rotavirus Vaccine Using a Mice Animal Model. <i>Viral Immunology</i> , 2016, 29, 565-571.	0.6	4
414	Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus. <i>Scientific Reports</i> , 2016, 6, 25735.	1.6	23
415	Measuring indirect effects of rotavirus vaccine in low income countries. <i>Vaccine</i> , 2016, 34, 4351-4353.	1.7	22
416	Genetic diversity of rotavirus strains in children with diarrhea in Lagos, Nigeria. <i>Asian Pacific Journal of Tropical Disease</i> , 2016, 6, 517-520.	0.5	5
417	Systems Approach to Climate, Water, and Diarrhea in Hubli-Dharwad, India. <i>Environmental Science & Technology</i> , 2016, 50, 13042-13051.	4.6	15

#	ARTICLE	IF	CITATIONS
418	Chronic Health Consequences of Acute Enteric Infections in the Developing World. American Journal of Gastroenterology Supplements (Print), 2016, 3, 4-11.	0.7	25
419	Monovalent Rotavirus Vaccine Effectiveness and Impact on Rotavirus Hospitalizations in Zanzibar, Tanzania: Data From the First 3 Years After Introduction. Journal of Infectious Diseases, 2017, 215, jiw524.	1.9	30
420	Changing distribution of age, clinical severity, and genotypes of rotavirus gastroenteritis in hospitalized children after the introduction of vaccination: a single center study in Seoul between 2011 and 2014. BMC Infectious Diseases, 2016, 16, 287.	1.3	16
421	Editorials. Indian Pediatrics, 2016, 53, 565-568.	0.2	9
422	A Comparison of Diarrheal Severity Scores in the MALÉD Multisite Community-Based Cohort Study. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 466-473.	0.9	27
423	Incidence of rotavirus gastroenteritis by age in African, Asian and European children: Relevance for timing of rotavirus vaccination. Human Vaccines and Immunotherapeutics, 2016, 12, 2406-2412.	1.4	36
424	Use of Patients With Diarrhea Who Test Negative for Rotavirus as Controls to Estimate Rotavirus Vaccine Effectiveness Through Case-Control Studies. Clinical Infectious Diseases, 2016, 62, S106-S114.	2.9	26
425	Impact of Rotavirus Vaccination on Diarrheal Hospitalizations in Children Aged <5 Years in Lusaka, Zambia. Clinical Infectious Diseases, 2016, 62, S183-S187.	2.9	57
426	Temporal Association of Rotavirus Vaccine Introduction and Reduction in All-Cause Childhood Diarrheal Hospitalizations in South Africa. Clinical Infectious Diseases, 2016, 62, S188-S195.	2.9	42
427	A Preliminary Assessment of Rotavirus Vaccine Effectiveness in Zambia. Clinical Infectious Diseases, 2016, 62, S175-S182.	2.9	40
428	Effectiveness of Monovalent Rotavirus Vaccine After Programmatic Implementation in Botswana: A Multisite Prospective Case-Control Study. Clinical Infectious Diseases, 2016, 62, S161-S167.	2.9	66
429	Impact of Rotavirus Vaccination on Hospitalizations and Deaths From Childhood Gastroenteritis in Botswana. Clinical Infectious Diseases, 2016, 62, S168-S174.	2.9	48
430	Impact and Effectiveness of Monovalent Rotavirus Vaccine Against Severe Rotavirus Diarrhea in Ghana. Clinical Infectious Diseases, 2016, 62, S200-S207.	2.9	86
431	Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial. Journal of Infectious Diseases, 2016, 213, 1686-1693.	1.9	44
432	Issues in pediatric vaccine-preventable diseases in low- to middle-income countries. Human Vaccines and Immunotherapeutics, 2016, 12, 2365-2377.	1.4	18
433	Success of rotavirus vaccination in Africa: good news and remaining questions. The Lancet Global Health, 2016, 4, e76-e77.	2.9	5
434	A Systematic Review of the Effect of Rotavirus Vaccination on Diarrhea Outcomes Among Children Younger Than 5 Years. Pediatric Infectious Disease Journal, 2016, 35, 992-998.	1.1	92
435	Effect of pentavalent rotavirus vaccine introduction on hospital admissions for diarrhoea and rotavirus in children in Rwanda: a time-series analysis. The Lancet Global Health, 2016, 4, e129-e136.	2.9	60

#	ARTICLE	IF	CITATIONS
436	Delayed Dosing of Oral Rotavirus Vaccine Demonstrates Decreased Risk of Rotavirus Gastroenteritis Associated With Serum Zinc: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 634-641.	2.9	54
437	Diversity in Rotavirusâ€™Host Glycan Interactions: A â€™Sweetâ€™Spectrum. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 263-273.	2.3	72
438	Effectiveness of Pentavalent Rotavirus Vaccine Under Conditions of Routine Use in Rwanda. <i>Clinical Infectious Diseases</i> , 2016, 62, S208-S212.	2.9	43
439	Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Guatemala. <i>Clinical Infectious Diseases</i> , 2016, 62, S121-S126.	2.9	25
440	Epidemiology of rotavirus A diarrhea in ChÃ³kwÃ³, Southern Mozambique, from February to September, 2011. <i>Journal of Medical Virology</i> , 2016, 88, 1751-1758.	2.5	18
441	Molecular characterisation of wild-type G1P[8] and G3P[8] rotaviruses isolated in Vietnam 2008 during a vaccine trial. <i>Archives of Virology</i> , 2016, 161, 833-850.	0.9	5
442	Expression of rotavirus VP6 protein: a comparison amongst <i>Escherichia coli</i> , <i>Pichia pastoris</i> and <i>Hansenula polymorpha</i> . <i>FEMS Yeast Research</i> , 2016, 16, fow001.	1.1	14
443	A Randomized, Controlled Trial of the Impact of Alternative Dosing Schedules on the Immune Response to Human Rotavirus Vaccine in Rural Ghanaian Infants. <i>Journal of Infectious Diseases</i> , 2016, 213, 1678-1685.	1.9	45
444	Can Changes to Scheduling Enhance the Performance of Rotavirus Vaccines in Low-Income Countries?. <i>Journal of Infectious Diseases</i> , 2016, 213, 1673-1675.	1.9	5
445	Global Vaccine and Immunization Research Forum: Opportunities and challenges in vaccine discovery, development, and delivery. <i>Vaccine</i> , 2016, 34, 1489-1495.	1.7	12
446	Beyond efficacy: The full public health impact of vaccines. <i>Vaccine</i> , 2016, 34, 1139-1147.	1.7	26
447	Detection of the emerging rotavirus G12P[8] genotype at high frequency in Brazil in 2014: Successive replacement of predominant strains after vaccine introduction. <i>Acta Tropica</i> , 2016, 156, 87-94.	0.9	21
448	Prevaccination Rotavirus Serum IgG and IgA Are Associated With Lower Immunogenicity of Live, Oral Human Rotavirus Vaccine in South African Infants. <i>Clinical Infectious Diseases</i> , 2016, 62, 157-165.	2.9	66
449	Association of elevated rotavirus-specific antibody titers with HBGA secretor status in Swedish individuals: The FUT2 gene as a putative susceptibility determinant for infection. <i>Virus Research</i> , 2016, 211, 64-68.	1.1	30
450	Prevention and Control of Childhood Pneumonia and Diarrhea. <i>Pediatric Clinics of North America</i> , 2016, 63, 67-79.	0.9	47
451	Microneedle patches for vaccination in developing countries. <i>Journal of Controlled Release</i> , 2016, 240, 135-141.	4.8	166
452	Innate Immune Factors in Mothers' Breast Milk and Their Lack of Association With Rotavirus Vaccine Immunogenicity in Nicaraguan Infants. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, 87-90.	0.6	11
453	Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design. <i>Vaccine</i> , 2017, 35, 184-190.	1.7	37

#	ARTICLE	IF	CITATIONS
454	Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1126-1135.	1.4	20
455	Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean. <i>BMC Pediatrics</i> , 2017, 17, 14.	0.7	51
456	Vaccine Impact Data Should Support Country Decision Making. <i>Journal of Infectious Diseases</i> , 2017, 215, 1634-1636.	1.9	1
457	Cytokines in the management of rotavirus infection: A systematic review of in vivo studies. <i>Cytokine</i> , 2017, 96, 152-160.	1.4	27
458	Histo-blood group antigens as receptors for rotavirus, new understanding on rotavirus epidemiology and vaccine strategy. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-8.	3.0	64
459	Global economic evaluations of rotavirus vaccines: A systematic review. <i>Vaccine</i> , 2017, 35, 3364-3386.	1.7	25
460	Correlates of protection for enteric vaccines. <i>Vaccine</i> , 2017, 35, 3355-3363.	1.7	54
461	Background rates of disease in Latin American children from a rotavirus vaccine study. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1916-1920.	1.4	6
462	Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1908-1915.	1.4	15
463	Rotavirus in Latin America: Current Situation and Perspectives. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, 1-2.	0.6	11
464	Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , 2017, 17, 843-853.	4.6	109
465	Etiology of Diarrhea, Nutritional Outcomes, and Novel Intestinal Biomarkers in Tanzanian Infants. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 64, 104-108.	0.9	8
466	Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger. <i>New England Journal of Medicine</i> , 2017, 376, 1121-1130.	13.9	141
467	A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. <i>Vaccine</i> , 2017, 35, 6228-6237.	1.7	92
468	An ensemble approach to predicting the impact of vaccination on rotavirus disease in Niger. <i>Vaccine</i> , 2017, 35, 5835-5841.	1.7	17
469	Estimating the full public health value of vaccination. <i>Vaccine</i> , 2017, 35, 6255-6263.	1.7	52
470	Impact of five years of rotavirus vaccination in Finland – And the associated cost savings in secondary healthcare. <i>Vaccine</i> , 2017, 35, 5611-5617.	1.7	22
471	Rotavirus virus-like particles (RV-LVPs) vaccines: An update. <i>Reviews in Medical Virology</i> , 2017, 27, e1954.	3.9	18

#	ARTICLE	IF	CITATIONS
472	Estimated reductions in hospitalizations and deaths from childhood diarrhea following implementation of rotavirus vaccination in Africa. <i>Expert Review of Vaccines</i> , 2017, 16, 987-995.	2.0	53
474	Impact of rotavirus vaccination on rotavirus and all-cause gastroenteritis in peri-urban Kenyan children. <i>Vaccine</i> , 2017, 35, 5217-5223.	1.7	16
475	Is rotavirus still a major cause for diarrheal illness in hospitalized pediatric patients after rotavirus vaccine introduction in the Saudi national immunization program?. <i>Medicine (United States)</i> , 2017, 96, e6574.	0.4	11
476	Hospital-based Surveillance for Rotavirus Gastroenteritis Among Young Children in Bangladesh. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 168-172.	1.1	40
477	Rotavirus infection. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17083.	18.1	419
478	Clean water, clean hands or new vaccines?. <i>Journal of Infection</i> , 2017, 74, S18-S22.	1.7	3
479	Child feeding practices and diarrheal disease among children less than two years of age of the nomadic people in Hadaleala District, Afar Region, Northeast Ethiopia. <i>International Breastfeeding Journal</i> , 2017, 12, 24.	0.9	35
480	Options for improving effectiveness of rotavirus vaccines in developing countries. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 921-927.	1.4	23
481	Acute Gastroenteritis Viruses. , 2017, , 1390-1398.e3.		3
482	Significant Correlation Between the Infant Gut Microbiome and Rotavirus Vaccine Response in Rural Ghana. <i>Journal of Infectious Diseases</i> , 2017, 215, 34-41.	1.9	227
483	Serologic response to porcine circovirus type 1 (PCV1) in infants vaccinated with the human rotavirus vaccine, <i>Rotarix</i> , [®] : A retrospective laboratory analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 237-244.	1.4	7
484	Whole-genome characterisation of G12P[6] rotavirus strains possessing two distinct genotype constellations co-circulating in Blantyre, Malawi, 2008. <i>Archives of Virology</i> , 2017, 162, 213-226.	0.9	11
485	Rotavirus vaccination and infection induce VP6-specific IgA responses. <i>Journal of Medical Virology</i> , 2017, 89, 239-245.	2.5	8
486	Contribution of Maternal Immunity to Decreased Rotavirus Vaccine Performance in Low- and Middle-Income Countries. <i>Vaccine Journal</i> , 2017, 24, .	3.2	30
487	Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors. <i>Expert Review of Vaccines</i> , 2018, 17, 1-17.	2.0	59
488	Are falls in the elderly less common in nursing homes compared with living at home?. <i>Evidence-Based Practice</i> , 2017, 20, 7-8.	0.0	0
489	Prevalence and characterization of rotaviruses in children hospitalized for diarrheal disease in a tertiary care hospital, Pune. <i>Indian Journal of Medical Microbiology</i> , 2017, 35, 33-36.	0.3	6
490	Differences of Rotavirus Vaccine Effectiveness by Country: Likely Causes and Contributing Factors. <i>Pathogens</i> , 2017, 6, 65.	1.2	105

#	ARTICLE	IF	CITATIONS
491	Investigating Potential Modes of Actions of Mimosa pudica Fruit Extract and Solvent Fractions for Their Antidiarrheal Activities in Mice. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-11.	0.5	14
492	Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. PLoS Medicine, 2017, 14, e1002282.	3.9	46
493	Rotavirus vaccine will have an impact in Asia. PLoS Medicine, 2017, 14, e1002298.	3.9	13
494	Using a monitoring and evaluation framework to improve study efficiency and quality during a prospective cohort study in infants receiving rotavirus vaccination in El Alto, Bolivia: the Infant Nutrition, Inflammation, and Diarrheal Illness (NIDI) study. BMC Public Health, 2017, 17, 911.	1.2	5
495	The public health value of vaccines beyond efficacy: methods, measures and outcomes. BMC Medicine, 2017, 15, 138.	2.3	63
496	Rotavirus Vaccine Schedules and Vaccine Response Among Infants in Low- and Middle-Income Countries: A Systematic Review. Open Forum Infectious Diseases, 2017, 4, ofx066.	0.4	11
497	A Rapid Epidemiological Tool to Measure the Burden of Norovirus Infection and Disease in Resource-Limited Settings. Open Forum Infectious Diseases, 2017, 4, ofx049.	0.4	17
498	Rotavirus hospitalizations among children <5 years of age—Tajikistan, 2013–2014. Vaccine, 2018, 36, 7794-7797.	1.7	3
499	Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Coadministered With Measles, Yellow Fever, and Meningitis A Vaccines in 9-Month-Old Malian Infants. Journal of Infectious Diseases, 2018, 218, 606-613.	1.9	23
500	Evaluation of Intussusception after Monovalent Rotavirus Vaccination in Africa. New England Journal of Medicine, 2018, 378, 1521-1528.	13.9	93
501	Rotavirus Vaccines: A Social Injustice Story. Journal of Tropical Pediatrics, 2018, 64, 1-3.	0.7	2
502	Administration of Lactococcus lactis strain Plasma induces maturation of plasmacytoid dendritic cells and protection from rotavirus infection in suckling mice. International Immunopharmacology, 2018, 56, 205-211.	1.7	10
503	Rotaviruses. , 2018, , 1122-1125.e3.		3
504	The Lewis A phenotype is a restriction factor for Rotateq and Rotarix vaccine-take in Nicaraguan children. Scientific Reports, 2018, 8, 1502.	1.6	55
505	Rotavirus Vaccines: Effectiveness, Safety, and Future Directions. Paediatric Drugs, 2018, 20, 223-233.	1.3	83
506	Rotavirus Vaccines: Why Continued Investment in Research Is Necessary. Current Clinical Microbiology Reports, 2018, 5, 73-81.	1.8	6
507	Causes of impaired oral vaccine efficacy in developing countries. Future Microbiology, 2018, 13, 97-118.	1.0	154
508	Distributional cost-effectiveness analysis in low- and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia. Health Policy and Planning, 2018, 33, 456-463.	1.0	25

#	ARTICLE	IF	CITATIONS
509	Rotavirus and norovirus in children with severe diarrhea in Burkina Faso before rotavirus vaccine introduction. <i>Journal of Medical Virology</i> , 2018, 90, 1453-1460.	2.5	17
510	The influence of incomplete case ascertainment on measures of vaccine efficacy. <i>Vaccine</i> , 2018, 36, 2946-2952.	1.7	7
511	Timing and predictors of severe rotavirus gastroenteritis among unvaccinated infants in low- and middle-income countries. <i>Epidemiology and Infection</i> , 2018, 146, 698-704.	1.0	0
512	Impact of pentavalent rotavirus vaccine against severe rotavirus diarrhoea in The Gambia. <i>Vaccine</i> , 2018, 36, 7179-7184.	1.7	2
513	Antibody secreting B cells and plasma antibody response to rotavirus vaccination in infants from Kolkata India. <i>Heliyon</i> , 2018, 4, e00519.	1.4	7
514	Pertussis and Rotavirus Vaccines – Controversies and Solutions. <i>Indian Journal of Pediatrics</i> , 2018, 85, 53-59.	0.3	3
515	Impact of rotavirus vaccine on all-cause diarrhea and rotavirus hospitalizations in Madagascar. <i>Vaccine</i> , 2018, 36, 7198-7204.	1.7	11
516	Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan. <i>Gut Microbes</i> , 2018, 9, 93-101.	4.3	142
517	Viral Gastroenteritis. , 2018, , 383-387.e3.		1
518	Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 189-198.	1.4	15
519	Phylogenetic comparison of the VP7, VP4, VP6, and NSP4 genes of rotaviruses isolated from children in Nizhny Novgorod, Russia, 2015–2016, with cogent genes of the Rotarix and RotaTeq vaccine strains. <i>Virus Genes</i> , 2018, 54, 225-235.	0.7	11
520	Immunization of Mice by Rotavirus NSP4-VP6 Fusion Protein Elicited Stronger Responses Compared to VP6 Alone. <i>Viral Immunology</i> , 2018, 31, 233-241.	0.6	8
521	Influence of the intestinal microbiota on the immunogenicity of oral rotavirus vaccine given to infants in south India. <i>Vaccine</i> , 2018, 36, 264-272.	1.7	88
522	Impact of rotavirus vaccine on rotavirus diarrhoea in countries of East and Southern Africa. <i>Vaccine</i> , 2018, 36, 7124-7130.	1.7	21
523	Improving rotavirus vaccine coverage: Can newer-generation and locally produced vaccines help?. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 495-499.	1.4	23
524	Early impact of rotavirus vaccine in under 5 year old children hospitalized due to diarrhea, Swaziland. <i>Vaccine</i> , 2018, 36, 7210-7214.	1.7	4
525	Influence of vaccination status and clinical, seasonal and sociodemographic factors on rotavirus prevalence in KwaZulu-Natal, South Africa. <i>Southern African Journal of Infectious Diseases</i> , 2018, , 1-7.	0.3	0
526	Timing of Rotavirus Vaccine Doses and Severe Rotavirus Gastroenteritis Among Vaccinated Infants in Low- and Middle-income Countries. <i>Epidemiology</i> , 2018, 29, 867-875.	1.2	5

#	ARTICLE	IF	CITATIONS
527	Effectiveness of the Oral Human Attenuated Rotavirus Vaccine: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy292.	0.4	20
528	Measuring human capital: a systematic analysis of 195 countries and territories, 1990–2016. <i>Lancet</i> , The, 2018, 392, 1217-1234.	6.3	115
529	Bioengineered Norovirus S ₆₀ Nanoparticles as a Multifunctional Vaccine Platform. <i>ACS Nano</i> , 2018, 12, 10665-10682.	7.3	28
530	Efficacy and Effectiveness of Rotavirus Vaccine on Incidence of Diarrhoea among Children: A Meta-analysis. <i>Pediatric Infectious Diseases Open Access</i> , 2018, 03, .	0.0	2
531	Whole-genome sequencing and analyses identify high genetic heterogeneity, diversity and endemicity of rotavirus genotype P[6] strains circulating in Africa. <i>Infection, Genetics and Evolution</i> , 2018, 63, 79-88.	1.0	26
532	Oral immunization with rotavirus VP7-CTB fusion expressed in transgenic <i>Arabidopsis thaliana</i> induces antigen-specific IgA and IgG and passive protection in mice. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 4866-4874.	0.8	3
533	Safety of a heat-stable rotavirus vaccine among children in Niger: Data from a phase 3, randomized, double-blind, placebo-controlled trial. <i>Vaccine</i> , 2018, 36, 3674-3680.	1.7	18
534	Retinoic acid elicits a coordinated expression of gut homing markers on T lymphocytes of Zambian men receiving oral Vivotif, but not Rotarix, Dukoral or OPVERO vaccines. <i>Vaccine</i> , 2018, 36, 4134-4141.	1.7	6
535	Impact of rotavirus vaccines in Sub-Saharan African countries. <i>Vaccine</i> , 2018, 36, 7119-7123.	1.7	35
536	Viral gastroenteritis. <i>Lancet</i> , The, 2018, 392, 175-186.	6.3	283
537	Developing effective vaccines: Cues from natural infection. <i>International Reviews of Immunology</i> , 2018, 37, 249-265.	1.5	10
538	Surveillance Study of Acute Gastroenteritis Etiologies in Hospitalized Children in South Lebanon (SAGE study). <i>Pediatric Gastroenterology, Hepatology and Nutrition</i> , 2018, 21, 176.	0.4	19
539	Composition of gut microbiota and its influence on the immunogenicity of oral rotavirus vaccines. <i>Vaccine</i> , 2018, 36, 3427-3433.	1.7	26
540	Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2082-2087.	1.4	1
541	Quantifying the Impact of Natural Immunity on Rotavirus Vaccine Efficacy Estimates: A Clinical Trial in Dhaka, Bangladesh (PROVIDE) and a Simulation Study. <i>Journal of Infectious Diseases</i> , 2018, 217, 861-868.	1.9	32
542	Acute malnutrition among children aged 6–59 months of the nomadic population in Hadaleala district, Afar region, northeast Ethiopia. <i>Italian Journal of Pediatrics</i> , 2018, 44, 21.	1.0	18
543	Impact of monovalent rotavirus vaccine on diarrhoea-associated post-neonatal infant mortality in rural communities in Malawi: a population-based birth cohort study. <i>The Lancet Global Health</i> , 2018, 6, e1036-e1044.	2.9	41
544	Rotavirus vaccine impact in Africa: greater than the sum of its parts?. <i>The Lancet Global Health</i> , 2018, 6, e948-e949.	2.9	10

#	ARTICLE	IF	CITATIONS
545	Enhancing Rotavirus Vaccination: A Microbial Fix?. Cell Host and Microbe, 2018, 24, 195-196.	5.1	4
546	Update on vaccines for enteric pathogens. Clinical Microbiology and Infection, 2018, 24, 1039-1045.	2.8	42
547	Diversity of rotavirus strains circulating in children under five years of age who presented with acute gastroenteritis before and after rotavirus vaccine introduction, University Teaching Hospital, Lusaka, Zambia, 2008-2015. Vaccine, 2018, 36, 7243-7247.	1.7	22
548	Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction. Vaccine, 2018, 36, 7142-7148.	1.7	23
549	Community Protection. , 2018, , 1512-1531.e5.		17
550	Vaccination of Human Immunodeficiency Virus-Infected Persons. , 2018, , 1370-1382.e8.		0
551	Rotavirus Vaccines. , 2018, , 950-969.e11.		3
552	New pentavalent rotavirus vaccine shows little efficacy against diarrhea. Vaccine, 2019, 37, 3945.	1.7	1
553	Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi. Science Translational Medicine, 2019, 11, .	5.8	25
554	Vaccines for enteric diseases. Human Vaccines and Immunotherapeutics, 2019, 15, 1205-1214.	1.4	11
555	Recent Trends in Microneedle Development & Applications in Medicine and Cosmetics (2013-2018). , 2019, , 95-144.		3
556	Molecular characterization of G2P[4] and G9P[8] rotaviruses strains isolated from Moroccan children fully vaccinated with Rotarix, between 2013 and 2014. Alexandria Journal of Medicine, 2019, 55, 7-14.	0.4	0
557	Microneedles for Transdermal Drug Delivery. , 2019, , .		7
558	Increased T Cell Differentiation and Cytolytic Function in Bangladeshi Compared to American Children. Frontiers in Immunology, 2019, 10, 2239.	2.2	14
559	Vaccines for preventing rotavirus diarrhoea: vaccines in use. The Cochrane Library, 2019, 3, CD008521.	1.5	47
560	Implications and measurement of herd protection (indirect effects) for enteric vaccine development. Vaccine, 2019, 37, 4775-4777.	1.7	4
561	Rice bran supplementation modulates growth, microbiota and metabolome in weaning infants: a clinical trial in Nicaragua and Mali. Scientific Reports, 2019, 9, 13919.	1.6	31
562	Association Between Rotavirus Vaccination and Risk of Intussusception Among Neonates and Infants. JAMA Network Open, 2019, 2, e1912458.	2.8	27

#	ARTICLE	IF	CITATIONS
563	Prevention of Rotavirus Diarrhea in Suckling Rats by a Specific Fermented Milk Concentrate with Prebiotic Mixture. <i>Nutrients</i> , 2019, 11, 189.	1.7	34
564	A new tuberculosis vaccine: breakthrough, challenges, and a call for collaboration. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 123-125.	4.6	8
565	Interventions to improve oral vaccine performance: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 203-214.	4.6	51
566	Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice. <i>Vaccine</i> , 2019, 37, 4103-4110.	1.7	18
567	Surveying Gut Microbiome Research in Africans: Toward Improved Diversity and Representation. <i>Trends in Microbiology</i> , 2019, 27, 824-835.	3.5	51
568	A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC [®] in comparison with a licensed rotavirus vaccine in healthy infants. <i>Vaccine</i> , 2019, 37, 4407-4413.	1.7	14
569	The distinct impact of maternal antibodies on the immunogenicity of live and recombinant rotavirus vaccines. <i>Vaccine</i> , 2019, 37, 4061-4067.	1.7	7
570	Evolution of P[8], P[4], and P[6] VP8* genes of human rotaviruses globally reported during 1974 and 2017: possible implications for rotavirus vaccines in development. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 3003-3008.	1.4	7
571	Reviewing the evidence on breast milk composition and immunological outcomes. <i>Nutrition Reviews</i> , 2019, 77, 541-556.	2.6	63
572	Impact of rotavirus vaccination on childhood hospitalizations for seizures: Heterologous or unforeseen direct vaccine effects?. <i>Vaccine</i> , 2019, 37, 3362-3368.	1.7	11
573	New vaccine introductions in Africa before and during the decade of vaccines “Are we making progress?”. <i>Vaccine</i> , 2019, 37, 3290-3295.	1.7	14
574	Post-vaccinated asymptomatic rotavirus infections: A community profile study of children in Surabaya, Indonesia. <i>Journal of Infection and Public Health</i> , 2019, 12, 625-629.	1.9	14
575	Histo-Blood Group Antigens in Children with Symptomatic Rotavirus Infection. <i>Viruses</i> , 2019, 11, 339.	1.5	38
576	A phase I trial of WRSS1, a <i>Shigella sonnei</i> live oral vaccine in Bangladeshi adults and children. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1326-1337.	1.4	24
577	Enhancing immune responses to oral vaccines: still an enigma. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 122-123.	4.6	2
578	The Impact of Improved Water, Sanitation, and Hygiene on Oral Rotavirus Vaccine Immunogenicity in Zimbabwean Infants: Substudy of a Cluster-randomized Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 2074-2081.	2.9	15
579	Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1215-1227.	1.4	50
580	Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of Age Presenting for Medical Care With Diarrhea in Rural Matlab, Bangladesh. <i>Clinical Infectious Diseases</i> , 2019, 69, 2059-2070.	2.9	8

#	ARTICLE	IF	CITATIONS
581	The ORVAC trial protocol: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis. <i>BMJ Open</i> , 2019, 9, e032549.	0.8	11
582	Rotavirus symptomatic infection among unvaccinated and vaccinated children in Valencia, Spain. <i>BMC Infectious Diseases</i> , 2019, 19, 998.	1.3	7
583	Early-life programming of mesenteric lymph node stromal cell identity by the lymphotoxin pathway regulates adult mucosal immunity. <i>Science Immunology</i> , 2019, 4, .	5.6	23
584	Rotavirus vaccine efficacy: current status and areas for improvement. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1237-1250.	1.4	37
585	Approaches to monitoring intussusception following rotavirus vaccination. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 21-27.	1.0	8
586	Would immunization be the same without cross-reactivity?. <i>Vaccine</i> , 2019, 37, 539-549.	1.7	26
587	A Liposome-Based Adjuvant Containing Two Delivery Systems with the Ability to Induce Mucosal Immunoglobulin A Following a Parenteral Immunization. <i>ACS Nano</i> , 2019, 13, 1116-1126.	7.3	22
588	Rotavirus VP6 as a potential vaccine candidate. <i>Reviews in Medical Virology</i> , 2019, 29, e2027.	3.9	20
589	Diarrheal Etiology and Impact of Coinfections on Rotavirus Vaccine Efficacy Estimates in a Clinical Trial of a Monovalent Humanâ€“Bovine (116E) Oral Rotavirus Vaccine, Rotavac, India. <i>Clinical Infectious Diseases</i> , 2019, 69, 243-250.	2.9	23
590	Multiple Introductions and Antigenic Mismatch with Vaccines May Contribute to Increased Predominance of G12P[8] Rotaviruses in the United States. <i>Journal of Virology</i> , 2019, 93, .	1.5	31
591	Immunogenicity of different dosing schedules of the human live attenuate rotavirus vaccine (RV1) in infants and children: a meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1228-1236.	1.4	5
592	Influence of Nonpolio Enteroviruses and the Bacterial Gut Microbiota on Oral Poliovirus Vaccine Response: A Study from South India. <i>Journal of Infectious Diseases</i> , 2019, 219, 1178-1186.	1.9	34
593	Factors Associated with Severe Dehydrating Diarrhoea in the Rural Western Cape, South Africa. <i>Journal of Tropical Pediatrics</i> , 2019, 65, 1-8.	0.7	4
594	The rotavirus vaccine development pipeline. <i>Vaccine</i> , 2019, 37, 7328-7335.	1.7	93
595	Evidence for Household Transmission of Rotavirus in the United States, 2011â€“2016. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 181-187.	0.6	13
596	Evaluation of Intussusception After Oral Monovalent Rotavirus Vaccination in South Africa. <i>Clinical Infectious Diseases</i> , 2020, 70, 1606-1612.	2.9	37
597	Precision immunization: a new trend in human vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 513-522.	1.4	8
598	Effectiveness of Monovalent Rotavirus Vaccine Against Hospitalization With Acute Rotavirus Gastroenteritis in Kenyan Children. <i>Clinical Infectious Diseases</i> , 2020, 70, 2298-2305.	2.9	28

#	ARTICLE	IF	CITATIONS
599	Worldwide Emerging and Reemerging Rotavirus Genotypes: Genetic Variability and Interspecies Transmission in Health and Environment. , 2020, , 1017-1040.		1
600	Identifying signatures of the impact of rotavirus vaccines on hospitalizations using sentinel surveillance data from Latin American countries. Vaccine, 2020, 38, 323-329.	1.7	6
601	Reverse Genetics System for a Human Group A Rotavirus. Journal of Virology, 2020, 94, .	1.5	33
602	Systems Biological Approaches for Mucosal Vaccine Development. , 2020, , 753-772.		2
603	Human Neonatal Rotavirus Vaccine (RV3-BB) Produces Vaccine Take Irrespective of Histo-Blood Group Antigen Status. Journal of Infectious Diseases, 2020, 221, 1070-1078.	1.9	18
604	Cross-Cumulation Arrangement as FTA Under GATT Article XXIV. Journal of International Economic Law, 2020, 23, 165-185.	0.7	1
605	VP7 and VP4 genotypes of rotaviruses cocirculating in Iran, 2015 to 2017: Comparison with cogent sequences of Rotarix and RotaTeq vaccine strains before their use for universal mass vaccination. Journal of Medical Virology, 2020, 92, 1110-1123.	2.5	12
606	Retrospective Case-Control Study of 2017 G2P[4] Rotavirus Epidemic in Rural and Remote Australia. Pathogens, 2020, 9, 790.	1.2	10
607	Analysis of Fecal Sludges Reveals Common Enteric Pathogens in Urban Maputo, Mozambique. Environmental Science and Technology Letters, 2020, 7, 889-895.	3.9	27
608	Reverse Genetics Approach for Developing Rotavirus Vaccine Candidates Carrying VP4 and VP7 Genes Cloned from Clinical Isolates of Human Rotavirus. Journal of Virology, 2020, 95, .	1.5	20
609	Rotavirus Genotypes in Hospitalized Children With Acute Gastroenteritis Before and After Rotavirus Vaccine Introduction in Blantyre, Malawi, 1997â€“2019. Journal of Infectious Diseases, 2020, , .	1.9	13
610	Impact of the intestinal environment on the immune responses to vaccination. Vaccine, 2020, 38, 6959-6965.	1.7	12
611	The Impact of the Microbiome on Immunity to Vaccination in Humans. Cell Host and Microbe, 2020, 28, 169-179.	5.1	104
612	Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned. Expert Review of Vaccines, 2020, 19, 755-769.	2.0	11
613	Evaluation of the safety profile of rotavirus vaccines: a pharmacovigilance analysis on American and European data. Scientific Reports, 2020, 10, 13601.	1.6	9
614	Immunogenicity and Safety of Porcine Circovirus-Free Human Rotavirus Vaccine in Healthy Infants: A Phase 3 Randomized Trial. Journal of Infectious Diseases, 2020, , .	1.9	3
615	Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial. Trials, 2020, 21, 435.	0.7	5
616	Report of the 1st African Enteric Viruses Genome Initiative (AEVGI) Data and Bioinformatics Workshop on whole-genome analysis of some African rotavirus strains held in Bloemfontein, South Africa. Vaccine, 2020, 38, 5402-5407.	1.7	5

#	ARTICLE	IF	CITATIONS
617	Modeling of rotavirus transmission dynamics and impact of vaccination in Ghana. <i>Vaccine</i> , 2020, 38, 4820-4828.	1.7	10
618	An overview of rotavirus vaccination programs in developing countries. <i>Expert Review of Vaccines</i> , 2020, 19, 529-537.	2.0	16
619	Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines. <i>Vaccines</i> , 2020, 8, 341.	2.1	24
620	Assessment of risk of intussusception after pilot rollout of rotavirus vaccine in the Indian public health system. <i>Vaccine</i> , 2020, 38, 5241-5248.	1.7	11
621	Predictors of oral rotavirus vaccine immunogenicity in rural Zimbabwean infants. <i>Vaccine</i> , 2020, 38, 2870-2878.	1.7	11
622	Postvaccination Serum Antirotavirus Immunoglobulin A as a Correlate of Protection Against Rotavirus Gastroenteritis Across Settings. <i>Journal of Infectious Diseases</i> , 2020, 222, 309-318.	1.9	21
623	Holistic process development to mitigate proteolysis of a subunit rotavirus vaccine candidate produced in <i>Pichia pastoris</i> by means of an acid pH pulse during fed-batch fermentation. <i>Biotechnology Progress</i> , 2020, 36, e2966.	1.3	12
624	Impact of vaccination on the risk factors for acute rotavirus diarrhea: An analysis of the data of a cluster randomized trial conducted in a rural area of Bangladesh. <i>Vaccine</i> , 2020, 38, 2190-2197.	1.7	8
625	Immune predictors of oral poliovirus vaccine immunogenicity among infants in South India. <i>Npj Vaccines</i> , 2020, 5, 27.	2.9	3
626	Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia. <i>Vaccine</i> , 2020, 38, 3235-3242.	1.7	2
627	Clinical and Environmental Surveillance of Rotavirus Common Genotypes Showed High Prevalence of Common P Genotypes in Egypt. <i>Food and Environmental Virology</i> , 2020, 12, 99-117.	1.5	13
628	TIPICO X: report of the 10th interactive infectious disease workshop on infectious diseases and vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 759-772.	1.4	1
629	Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine. <i>Vaccine</i> , 2021, 39, 263-271.	1.7	15
630	The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 880-896.	1.4	7
631	The Role of Vaccines in Combating Antimicrobial Resistance. <i>Sustainable Agriculture Reviews</i> , 2021, , 347-430.	0.6	3
632	Genetic characterization of G12P[6] and G12P[8] rotavirus strains collected in six African countries between 2010 and 2014. <i>BMC Infectious Diseases</i> , 2021, 21, 107.	1.3	7
633	Chapter Two: Literature Review. , 2021, , 22-31.		0
634	Rapid and sensitive detection of rotavirus by surface-enhanced Raman scattering immunochromatography. <i>Mikrochimica Acta</i> , 2021, 188, 3.	2.5	14

#	ARTICLE	IF	CITATIONS
635	Cord Blood-Based Approach to Assess Candidate Vaccine Adjuvants Designed for Neonates and Infants. <i>Vaccines</i> , 2021, 9, 95.	2.1	7
636	Genetic diversity of G9 rotavirus strains circulating among diarrheic children in North India: A comparison with 116E rotavirus vaccine strain. <i>Vaccine</i> , 2021, 39, 646-651.	1.7	2
637	A Nanoparticle-Based Trivalent Vaccine Targeting the Glycan Binding VP8* Domains of Rotaviruses. <i>Viruses</i> , 2021, 13, 72.	1.5	12
638	Association between circulating rotavirus genotypes and histo-blood group antigens in the children hospitalized with acute gastroenteritis in Iran. <i>Journal of Medical Virology</i> , 2021, 93, 4817-4823.	2.5	9
639	Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins. <i>Archives of Virology</i> , 2021, 166, 995-1006.	0.9	9
640	Established and new rotavirus vaccines: a comprehensive review for healthcare professionals. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-17.	1.4	10
641	Effectiveness of the oral human attenuated pentavalent rotavirus vaccine (RotaTeq [®]) postlicensure: a meta-analysis 2006–2020. <i>Expert Review of Vaccines</i> , 2021, 20, 1-12.	2.0	2
642	Impact of sampling depth on pathogen detection in pit latrines. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009176.	1.3	17
643	Force of infection: a determinant of vaccine efficacy?. <i>Npj Vaccines</i> , 2021, 6, 51.	2.9	19
644	Association of Rotavirus Vaccines With Reduction in Rotavirus Gastroenteritis in Children Younger Than 5 Years. <i>JAMA Pediatrics</i> , 2021, 175, e210347.	3.3	21
645	Effectiveness of rotavirus vaccine in preventing transmission of rotavirus from children to household contacts in Malawi. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 590-591.	4.6	0
646	Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 731-740.	4.6	14
647	Effects of schistosomes on host anti-viral immune response and the acquisition, virulence, and prevention of viral infections: A systematic review. <i>PLoS Pathogens</i> , 2021, 17, e1009555.	2.1	10
648	Detection of diarrhoea associated rotavirus and co-infection with diarrhoeagenic pathogens in the Littoral region of Cameroon using ELISA, RT-PCR and Luminex xTAG GPP assays. <i>BMC Infectious Diseases</i> , 2021, 21, 614.	1.3	4
649	Impact of Rotavirus Vaccine Introduction on Rotavirus Hospitalizations Among Children Under 5 Years of Age—World Health Organization African Region, 2008–2018. <i>Clinical Infectious Diseases</i> , 2021, 73, 1605-1608.	2.9	2
650	Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. <i>Vaccine</i> , 2021, 39, 3696-3716.	1.7	26
651	Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003655.	3.9	10
652	Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 811-819.	0.7	1

#	ARTICLE	IF	CITATIONS
653	Rotavirus vaccines performance: dynamic interdependence of host, pathogen and environment. <i>Expert Review of Vaccines</i> , 2021, 20, 945-957.	2.0	10
654	Is the Rotavirus Vaccine Really Associated with a Decreased Risk of Developing Celiac and Other Autoimmune Diseases?. <i>Rambam Maimonides Medical Journal</i> , 2021, 12, .	0.4	1
655	Immunogenicity of an oral rotavirus vaccine administered with prenatal nutritional support in Niger: A cluster randomized clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003720.	3.9	12
656	Global Experience With Rotavirus Vaccines. <i>Journal of Infectious Diseases</i> , 2021, 224, S792-S800.	1.9	8
657	Structural basis of P[II] rotavirus evolution and host ranges under selection of histo-blood group antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	9
658	The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease. <i>Journal of Infectious Diseases</i> , 2021, 224, S331-S342.	1.9	21
659	Etiology and Incidence of Moderate-to-Severe Diarrhea in Young Children in Niger. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 1062-1070.	0.6	12
660	Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. <i>Vaccine</i> , 2021, 39, 5513-5523.	1.7	16
661	Knowledge and attitude regarding rotavirus and its vaccination among medical students in Karachi, Pakistan. <i>Public Health in Practice</i> , 2021, 2, 100171.	0.7	0
663	Vaccines for preventing rotavirus diarrhoea: vaccines in use. <i>The Cochrane Library</i> , 2019, 2019, .	1.5	39
664	<i>Rotaviruses</i> . , 2014, , 713-732.		3
665	<i>Gut Immunology and Oral Vaccination</i> . , 2013, , 59-84.		3
666	<i>Acute Gastroenteritis in Children</i> . , 2011, , 1323-1339.e1.		18
667	<i>Rotaviruses</i> . , 2012, , 1094-1097.e3.		3
668	Pathophysiology of environmental enteric dysfunction and its impact on oral vaccine efficacy. <i>Mucosal Immunology</i> , 2018, 11, 1290-1298.	2.7	33
669	Rotavirus infection in Northern Territory before and after vaccination. <i>Microbiology Australia</i> , 2012, 33, 61.	0.1	10
670	Update on rotavirus vaccine underperformance in low- to middle-income countries and next-generation vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1787-1802.	1.4	30
671	Differential Profiles and Inhibitory Effect on Rotavirus Vaccines of Nonantibody Components in Breast Milk From Mothers in Developing and Developed Countries. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 863-870.	1.1	52

#	ARTICLE	IF	CITATIONS
672	Distribution of rotavirus VP7 and VP4 genotypes circulating in Tunisia from 2009 to 2014: Emergence of the genotype G12. <i>Journal of Medical Microbiology</i> , 2016, 65, 1028-1037.	0.7	17
674	Immune system development varies according to age, location, and anemia in African children. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	54
675	Lymph node fibrosis: a structural barrier to unleashing effective vaccine immunity. <i>Journal of Clinical Investigation</i> , 2018, 128, 2743-2745.	3.9	4
676	Understanding Reduced Rotavirus Vaccine Efficacy in Low Socio-Economic Settings. <i>PLoS ONE</i> , 2012, 7, e41720.	1.1	115
677	Chimaeric Virus-Like Particles Derived from Consensus Genome Sequences of Human Rotavirus Strains Co-Circulating in Africa. <i>PLoS ONE</i> , 2014, 9, e105167.	1.1	4
678	Population-Based Incidence Rates of Diarrheal Disease Associated with Norovirus, Sapovirus, and Astrovirus in Kenya. <i>PLoS ONE</i> , 2016, 11, e0145943.	1.1	37
679	Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States. <i>PLoS ONE</i> , 2016, 11, e0145977.	1.1	13
680	Norovirus Epidemiology in Africa: A Review. <i>PLoS ONE</i> , 2016, 11, e0146280.	1.1	64
681	Rotavirus Surveillance at a WHO-Coordinated Invasive Bacterial Disease Surveillance Site in Bangladesh: A Feasibility Study to Integrate Two Surveillance Systems. <i>PLoS ONE</i> , 2016, 11, e0153582.	1.1	10
682	Epidemiology, Seasonality and Factors Associated with Rotavirus Infection among Children with Moderate-to-Severe Diarrhea in Rural Western Kenya, 2008â€“2012: The Global Enteric Multicenter Study (GEMS). <i>PLoS ONE</i> , 2016, 11, e0160060.	1.1	23
683	Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets. <i>PLoS ONE</i> , 2016, 11, e0166038.	1.1	28
684	Immunogenicity of rotavirus vaccine (Rotarix TM) in infants with environmental enteric dysfunction. <i>PLoS ONE</i> , 2017, 12, e0187761.	1.1	18
685	Effect of innate antiviral glycoproteins in breast milk on seroconversion to rotavirus vaccine (Rotarix) in children in Lusaka, Zambia. <i>PLoS ONE</i> , 2017, 12, e0189351.	1.1	12
686	Estimating the incidence of rotavirus infection in children from India and Malawi from serial anti-rotavirus IgA titres. <i>PLoS ONE</i> , 2017, 12, e0190256.	1.1	9
687	Vaccines for Children in Low- and Middle-Income Countries. , 2016, , 187-204.		22
688	Rotavirus and its Genotype Distribution among Children Less than Three Years Presenting with Acute Watery Diarrhoea to a General Hospital in Urban Nepal. <i>Journal of Nepal Paediatric Society</i> , 2011, 31, 110-115.	0.1	2
689	Uncovering the First Atypical DS-1-like G1P[8] Rotavirus Strains That Circulated during Pre-Rotavirus Vaccine Introduction Era in South Africa. <i>Pathogens</i> , 2020, 9, 391.	1.2	13
690	Neonatal rhesus monkeys as an animal model for rotavirus infection. <i>World Journal of Gastroenterology</i> , 2018, 24, 5109-5119.	1.4	8

#	ARTICLE	IF	CITATIONS
691	Enteric Vaccines for Resource-Limited Countries: Current Status and Future Prospects. <i>Pediatric Annals</i> , 2011, 40, 351-357.	0.3	1
692	Successes, Challenges and Lessons Learned in Accelerating Introduction of Rotavirus Immunisation in Zambia. <i>World Journal of Vaccines</i> , 2015, 05, 43-53.	0.8	16
693	Molecular Characterization of Rotavirus Strains Circulating in Enugu Nigeria: 2011 to 2016. <i>World Journal of Vaccines</i> , 2019, 09, 22-36.	0.8	4
694	Association between Gut Microbiome Composition and Rotavirus Vaccine Response among Nicaraguan Infants. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 213-219.	0.6	35
695	Ten billion dollars pledged for 'decade of vaccines'. <i>Nature</i> , 0, , .	13.7	0
697	Injections that kill: nosocomial bacteraemia and degedege in Tanzania. <i>Rural and Remote Health</i> , 0, , .	0.4	3
698	Impact of rotavirus vaccination on childhood gastroenteriti. <i>Microbiology Australia</i> , 2012, 33, 56.	0.1	1
699	Viral Gastroenteritis. , 2012, , 377-381.e4.		1
700	Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix®,) in the Prevention of Rotavirus Gastroenteritis in Developing Countries. <i>Paediatric Drugs</i> , 2012, 14, 429-433.	1.3	3
702	Effectiveness of international aid for diarrheal disease control and potential for future impact. <i>Working Paper Series</i> , 2014, , .	0.7	1
703	Types of Rotavirus Causing Acute Diarrhea among Children in Western India, their Demographic Pattern and Disease Severity. <i>MGM Journal of Medical Sciences</i> , 2014, 1, 105-111.	0.1	1
704	Vacina contra o rotavirus nos cuidados de saúde de primários. <i>Revista Portuguesa De Clínica Geral</i> , 2014, 30, 78-82.	0.1	0
705	Eco-Epidemiology and Control of Waterborne Gastroenteritis: A Review. <i>Journal of Food Processing & Technology</i> , 2015, 06, .	0.2	1
706	Diarrheal Diseases. , 2016, , 361-372.		2
707	Rotavirus Vaccines: A Review of the Work, Progress, and Contributions Made in Latin America. , 2017, , 413-437.		2
708	Clinical and epidemiological features of the course of rotavirus infection and the justification of its prevention in children. <i>Áktualná Infektológia</i> , 2018, 6, 327-332.	0.1	0
710	Incidence of Rotavirus Infection among Under-Five Children Attending Health Centres in Selected Communities of Ndola, Copperbelt Province, Zambia. <i>Health</i> , 2019, 11, 298-307.	0.1	1
712	Vaccine Safety and Efficacy in Preventing Rotavirus Infection. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2019, 19, 215-224.	0.2	1

#	ARTICLE	IF	CITATIONS
713	Prevalence of <i>Cryptosporidium parvum</i> , <i>Giardia intestinalis</i> and molecular characterization of group A rotavirus associated with diarrhea in children below five years old in Gaborone, Botswana. Pan African Medical Journal, 2020, 37, 159.	0.3	4
714	0-5 Yaş Çocuklarda Rotavirüs Sıklığı ve Anne-Babaların Rotavirüse Yeterlilik Bilgi Düzeyleri ve Uygulamaları, 2020, 13, 124-130.		3
715	Investigation of two suspected diarrhoeal-illness outbreaks in Northern Cape and KwaZulu-Natal provinces, South Africa, April-July 2013: The role of rotavirus. Southern African Journal of Infectious Diseases, 2020, 35, 159.	0.3	2
716	Virus infections causing diarrhoea and vomiting. , 2020, , 797-805.		0
717	Gastrointestinal infections. , 2020, , 3008-3024.		0
720	Gastroenteritis in children. Clinical Evidence, 2011, 2011, .	0.2	0
721	Molecular epidemiology of group A human rotaviruses in North West region, Cameroon. Pan African Medical Journal, 2012, 12, 108.	0.3	7
722	The control of rotavirus gastroenteritis in the United States. Transactions of the American Clinical and Climatological Association, 2012, 123, 36-52; discussion 53.	0.9	17
724	Rotavirus vaccines: why continued investment in research is necessary. Current Clinical Microbiology Reports, 2018, 5, 73-81.	1.8	3
725	Plasma Rotavirus-specific IgA and Risk of Rotavirus Vaccine Failure in Infants in Malawi. Clinical Infectious Diseases, 2022, 75, 41-46.	2.9	11
726	Associations between biomarkers of environmental enteric dysfunction and oral rotavirus vaccine immunogenicity in rural Zimbabwean infants. EClinicalMedicine, 2021, 41, 101173.	3.2	3
727	Vaccines for preventing rotavirus diarrhoea: vaccines in use. The Cochrane Library, 2021, 2021, CD008521.	1.5	33
728	Rotavirus. Pediatrics in Review, 2012, 33, 439-447.	0.2	1
729	Effect of rotavirus genetic diversity on vaccine impact. Reviews in Medical Virology, 2022, 32, e2259.	3.9	23
730	The Role of Host Glycobiology and Gut Microbiota in Rotavirus and Norovirus Infection, an Update. International Journal of Molecular Sciences, 2021, 22, 13473.	1.8	13
731	Changes in Systemic Regulatory T Cells, Effector T Cells and Monocyte Populations Associated with Early Life Stunting. SSRN Electronic Journal, 0, , .	0.4	0
732	Co-administration of rotavirus nanospheres VP6 and NSP4 proteins enhanced the anti-NSP4 humoral responses in immunized mice. Microbial Pathogenesis, 2022, 163, 105405.	1.3	4
733	Closing the Global Immunization Gap: Delivery of Lifesaving Vaccines Through Innovation and Technology. Pediatrics in Review, 2014, 35, e32-e40.	0.2	2

#	ARTICLE	IF	CITATIONS
734	Understanding Rotavirus Vaccine Efficacy and Effectiveness in Countries with High Child Mortality. <i>Vaccines</i> , 2022, 10, 346.	2.1	30
735	Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 707 2184-2190.	1.7	3
736	The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality. <i>Vaccine</i> , 2022, 40, 1707-1711.	1.7	22
737	Effectiveness of Monovalent Rotavirus Vaccine in Mozambique, a Country with a High Burden of Chronic Malnutrition. <i>Vaccines</i> , 2022, 10, 449.	2.1	2
738	Genetic characterization of P[8] rotavirus strains circulated in Iran between 2009 and 2017. <i>Journal of Medical Virology</i> , 2022, 94, 3561-3569.	2.5	4
739	Vaccination of pregnant rhesus monkeys with inactivated rotavirus as a model for achieving protection from rotavirus SA11 infection in the offspring. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5656-5665.	1.4	3
740	Impact of maternal antibodies and microbiota development on the immunogenicity of oral rotavirus vaccine in African, Indian, and European infants. <i>Nature Communications</i> , 2021, 12, 7288.	5.8	26
741	Analysis of the intestinal microbial community altered during rotavirus infection in suckling mice. <i>Virology Journal</i> , 2021, 18, 254.	1.4	9
745	Rotaviruses: From Pathogenesis to Disease Control – A Critical Review. <i>Viruses</i> , 2022, 14, 875.	1.5	33
746	Immunity to enteric viruses. <i>Immunity</i> , 2022, 55, 800-818.	6.6	20
747	Association of Anti-Rotavirus IgA Seroconversion with Growth, Environmental Enteric Dysfunction and Enteropathogens in Rural Pakistani Infants. <i>Vaccine</i> , 2022, 40, 3444-3451.	1.7	1
748	Impact and effectiveness of monovalent rotavirus vaccine in Tajik children. <i>Vaccine</i> , 2022, , .	1.7	0
749	Shigella-Controlled Human Infection Models: Current and Future Perspectives. <i>Current Topics in Microbiology and Immunology</i> , 2021, , .	0.7	1
750	Hernia de Amyand, Manejo Quirúrgico ante un Diagnóstico Infrecuente. <i>Gaceta Medica Boliviana</i> , 2022, 45, .	0.0	0
751	Aging and Microbiome in the Modulation of Vaccine Efficacy. <i>Biomedicines</i> , 2022, 10, 1545.	1.4	3
752	Viral pathogens of acute gastroenteritis in Egyptian children: role of the parechovirus. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	4
753	Vaccines, adjuvants and key factors for mucosal immune response. <i>Immunology</i> , 2022, 167, 124-138.	2.0	17
754	A Pseudovirus Nanoparticle-Based Trivalent Rotavirus Vaccine Candidate Elicits High and Cross P Type Immune Response. <i>Pharmaceutics</i> , 2022, 14, 1597.	2.0	10

#	ARTICLE	IF	CITATIONS
755	Head-to-head comparison of the immunogenicity of RotaTaq and Rotarix rotavirus vaccines and factors associated with seroresponse in infants in Bangladesh: a randomised, controlled, open-label, parallel, phase 4 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1606-1616.	4.6	9
756	Morbidity, Mortality and the Impact of Climate on the Evolution of Acute Rotavirus Diarrhea in Children under 5 Years Old in Bangui. <i>Open Journal of Pediatrics</i> , 2022, 12, 607-632.	0.0	0
757	Monovalent Rotavirus Vaccine Efficacy Against Different Rotavirus Genotypes: A Pooled Analysis of Phase II and III Trial Data. <i>Clinical Infectious Diseases</i> , 2023, 76, e1150-e1156.	2.9	7
758	Circulating rotavirus P[8] lineage IV, unlike P[8] lineage III, significantly related to nonsecretors status in Iranian children. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	0
759	Systematic review of the effect of additional doses of oral rotavirus vaccine on immunogenicity and reduction in diarrhoeal disease among young children. <i>EClinicalMedicine</i> , 2022, 54, 101687.	3.2	4
760	Global burden and trends of rotavirus infection-associated deaths from 1990 to 2019: an observational trend study. <i>Virology Journal</i> , 2022, 19, .	1.4	30
762	Rotaviruses. , 2023, , 1141-1144.e3.		0
763	Viral Gastroenteritis. , 2023, , 395-400.e3.		0
764	The Challenges and Opportunities of Next-Generation Rotavirus Vaccines: Summary of an Expert Meeting with Vaccine Developers. <i>Viruses</i> , 2022, 14, 2565.	1.5	6
765	Review of the health impact of the oral rotavirus vaccine program in children under 5 years in Australia: 2006 to 2021. <i>Vaccine</i> , 2023, 41, 636-648.	1.7	3
766	Complete genome analyses of G12P[8] rotavirus strains from hospitalized children in Surabaya, Indonesia, 2017 to 2018. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	0
767	N-Glycosylation of Rotavirus NSP4 Protein Affects Viral Replication and Pathogenesis. <i>Journal of Virology</i> , 2023, 97, .	1.5	5
768	New Possibilities of Preventive Immunization for Rotavirus Infection in Russian Federation. Overview of the Innovative Rotavirus Vaccine Profile. <i>Pediatrica Eska i Farmakologia</i> , 2023, 19, 492-502.	0.1	4
769	Transporting monovalent rotavirus vaccine efficacy estimates to an external target population: a secondary analysis of data from a randomised controlled trial in Malawi. <i>Epidemiology and Infection</i> , 2023, 151, .	1.0	0
770	High Burden of Co-Infection with Multiple Enteric Pathogens in Children Suffering with Diarrhoea from Rural and Peri-Urban Communities in South Africa. <i>Pathogens</i> , 2023, 12, 315.	1.2	5
772	Changes in Systemic Regulatory T Cells, Effector T Cells, and Monocyte Populations Associated With Early-Life Stunting. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
773	Histo-Blood Group Antigen Null Phenotypes Associated With a Decreased Risk of Clinical Rotavirus Vaccine Failure Among Children <2 Years of Age Participating in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in Kenya, Mali, and the Gambia. <i>Clinical Infectious Diseases</i> , 2023, 76, S153-S161.	2.9	2
774	The Full Impact of Rotavirus Vaccines in Africa Has Yet to Be Realized. <i>Clinical Infectious Diseases</i> , 2023, 76, S1-S4.	2.9	3

#	ARTICLE	IF	CITATIONS
775	Prevalence, Clinical Severity, and Seasonality of Adenovirus 40/41, Astrovirus, Sapovirus, and Rotavirus Among Young Children With Moderate-to-Severe Diarrhea: Results From the Vaccine Impact on Diarrhea in Africa (VIDA) Study. <i>Clinical Infectious Diseases</i> , 2023, 76, S123-S131.	2.9	2
779	Reoviruses: Rotaviruses. , 2023, , 1-74.		0
781	Technologies for Making New Vaccines. , 2023, , 1350-1373.e9.		0
782	Rotavirus Vaccines. , 2023, , 1005-1024.e11.		0
783	Community Protection. , 2023, , 1603-1624.e8.		0
784	Rotavirus and Other Viral Diarrhoea. , 2024, , 246-253.		0
787	Immunological factors linked to geographical variation in vaccine responses. <i>Nature Reviews Immunology</i> , 0, , .	10.6	2
797	Rotavirus. , 2024, , 2321-2338.		0